Supplementum 194
ad Swiss Med Wkly
2012;142
August 11, 2012

Annual meeting of the
Swiss Society of Gastroenterology
Swiss Society of Visceral Surgery
Swiss Association of the Study of the Liver
Swiss Society of Clinical Nutrition
Interlaken (Switzerland), September 20–21, 2012
Suppl. 194
ad Swiss Med Wkly
2012;142
August 11, 2012

Oral presentations

Posters Gastroenterology

Posters Hepatology

Posters Surgery

Posters Interdisciplinary

Index of first authors
Protection of pharmacological postconditioning in liver surgery.

Results of a prospective randomized controlled trial.

Stefan Breitenstein, Beatrice Beck-Schimmer, John Bonvini, Michaal Lesurelt, Michael Ganter, Achim Weber, Milo A. Puhan, Pierre-Alain Clavien Department of Surgery and Institute of Anesthesiology, USZ, Zurich

Background: Targeted organ protection has gained increasing interest to improve perioperative outcomes. Inflow occlusion is an established procedure to reduce blood loss during liver transaction in elective patients, which is, however, potentially harmful due to the associated ischemia-reperfusion injury. Preventive strategies include the use of repetitive short periods of ischemia interrupted by a reperfusion phase (intermittent clamping), and the application of short period of ischemia prior to transaction (ischemic preconditioning) or some drugs prior to transaction (pharmacological preconditioning). However, whether interventions after resection (postconditioning) may confer protection is unknown.

Methods: A 3 arm-prospective randomized trial was designed in patients undergoing liver resection with inflow occlusion comparing the effects of pharmacological postconditioning with the volatile anesthetic sevoflurane (n=48), intermittent clamping (n=50) and no protective intervention (continuous inflow occlusion, n=17) based on proper sample size calculation. Endpoints included serum transaminase levels (AST), postoperative complications and hospital stay. All patients were intravenously anesthetized with propofol. In patients with postconditioning, propofol infusion was stopped upon reperfusion, and replaced by sevoflurane for 10 min.

Results: Compared to the control group, both postconditioning (p=0.04) and intermittent clamping (p=0.01) significantly reduced AST levels. The risk of any complications was significantly decreased by postconditioning (odds ratio 0.08 [0.02 to 0.36, p=0.001]) and intermittent clamping (odds ratio 0.50 [0.26 to 0.96, p=0.038]) compared to controls. Both interventions reduced length of hospital stay (postconditioning -4 days [-6 to -1, p=0.009], and intermittent clamping -2 days, [-4 to 0, p=0.019]).

Conclusions: This is the first trial demonstrating that pharmacological postconditioning reduces organ injury and importantly postoperative complications. This easily applicable strategy with clinically relevant benefits should be used in patients with prolonged continuous inflow occlusion.

Biotransformation of budesonide via cytochrome P450 3A enzymes in active eosinophilic esophagitis

Karin Dilger, MD, Luis Lopez-Lazaro, MD, Claudia Marx, MD, Christian Bussmann, MD, Alex Straumann, MD

Dr. Falk Pharma GmbH, Freiburg, Germany; 2Covance, Allschwil, Switzerland; 3Department of Pathology, Kantonsspital Lucerne, Lucerne, Switzerland; 4Swiss EoE Clinic, Olten, Switzerland

Background: Budesonide, a synthetic glucocorticoid with high local anti-inflammatory activity, has shown efficacy in patients with active eosinophilic esophagitis (EoE). However, clinical pharmacology of that model substrate of cytochrome P450 3A (CYP 3A) has not yet been investigated in this special population. Methods: Twelve adult patients with active EoE and twelve healthy adults received single and multiple dose treatment with budesonide containing orodispersible tablets (4 mg/day). Molar ratios of CYP3A dependent metabolite formation in plasma (AUCbudesonide/AUCbudesonide) were used as indices of CYP3A activity. Differences between subject groups were tested for significance using the Mann-Whitney test. Results: Metabolite formation was significantly impaired in patients with EoE as compared to healthy subjects. E.g., 19 ± 0.9 vs. 3.5 ± 1.1, 0.01; 6.9-60 budesonide following 4 mg budesonide single dose; 11.4 ± 6.2 vs. 20.5 ± 11.4, 0.035, 16b-hydroxybudesonide following 4 mg budesonide single dose. In parallel, systemic exposure to the parent compound (AUCbudesonide) following 4 mg of budesonide was significantly higher in patients with EoE than in healthy subjects. A patient reported outcome score showed significant relief of dysphagia following one week of continuous treatment with the new dosage form. Conclusions: Our data supports the new dosage form of budesonide as being a promising drug candidate in active EoE. Active eosinophilic inflammation of the esophageal mucosa is associated with reduced biotransformation of budesonide via CYP3A, the major subfamily of drug-metabolizing enzymes in humans.

PTEN protein phosphatase activity regulates HCV secretion through modulation of cholesterol metabolism

S. Clément (1), F. Negro (2,3), M. Foti (2,3), S. Conzelmann (1), V. Kaddai (1), M.Foto (2) and F. Negro (1,3)

(1) Divisions of Clinical Pathology and of (2) Gastroenterology and Hepatology, HUG, 2) Dept of Cellular Physiology and Metabolism, Faculty of Medicine, Geneva

Background: Hepatitis C virus (HCV) infection is dependent on lipid metabolism. Hepatocyte steatosis, i.e. excess neutral fat stored in large droplets (LD), occurs frequently in HCV infection, but the relationship between steatosis, HCV replication and virion production is unclear. We have shown that HCV induces steatosis via the downregulation of the phosphatase and tensin homologue deleted on chromosome 10 (PTEN). We now investigated how PTEN may affect HCV virion production.

Methods: The effect of overexpression or silencing of PTEN on HCV secretion was assessed in Huh-7 cells expressing the genomic-length Jc1 construct. The role of PTEN protein and lipid metabolism and secretion of infectious viral particles was investigated using dominant-negative PTEN mutants. The importance of cholesterol metabolism on PTEN-dependent LD biogenesis and viral particle secretion was examined using statins. Finally, we tested if PTEN silencing in Huh-7 cells infected with HCV stimulated viral particle secretion, while PTEN overexpression decreased virus egress. Viral secretion was also increased by overexpression of protein phosphatase-deleted PTEN (PTEN<sub>Y138L</sub>), but not lipid phosphatase-deleted (PTEN<sub>C125S</sub>). PTEN mutant, thus indicating that the protein phosphatase activity of PTEN controls virion secretion. Similarly, PTEN<sub>Y138L</sub>, but not PTEN<sub>C125S</sub>, mutant induced the formation of large LDs in the cytoplasm. PTEN<sub>Y138L</sub> mutant did not affect biosynthesis of triglycerides (TG), but promoted the biosynthesis of cholesterol esters (CE). Consistently, statins prevented the increased CE production, large LD formation and viral secretion in Huh-7 cells expressing the PTEN<sub>Y138L</sub> mutant.

Conclusion: Downregulation of PTEN protein phosphatase activity by HCV affects cholesterol metabolism thereby increasing CE synthesis, appearance of large LDs and release of viral particles.

Despite persistent high plasma levels pegylated Interferon-alpha only transiently induces interferon stimulated genes in the liver of patients with chronic hepatitis C

Michael T. Dietl 1,2, Zuzanna Makowska 1, Julia E. Vogt 3, Magdalena Filipowicz 1, Luigi Terracciano 1, Volker Roth 3, and Markus H. Heim 1,2

1 Department of Bioendoscopic Hepatology Laboratory, University of Basel
2 Division of Gastroenterology and Hepatology, University Hospital Basel
3 Computer Science Department, University of Basel
4 Institute of Pathology, University Hospital Basel

Background: Pegylated interferon-alpha (pegIFN-α) has replaced conventional IFN-α in the treatment of chronic hepatitis C (CHC) because it is more effective. Due to the prolonged half-life of PegIFN-α high serum concentrations can be achieved during the entire one-week dosing interval. It is generally believed that the improved pharmacokinetic properties of pegIFN-α result in an improved antiviral efficacy because of a continuous induction of the antiviral IFN stimulated genes (ISGs). However, pharmacodynamic studies in mice have shown that IFN-α induced signaling becomes refractory within hours after injection of IFN-α and remains unresponsive to further stimulation. In the present study we investigated the pharmacodynamics of pegIFN-α in liver biopsies obtained at various time points during the first week of treatment.

Methods: 18 patients with CHC had a second liver biopsy 4h (n=8), 16h, 48h, 96h or 144h (all n=3) after the first injection of pegIFN-α. Additional 3 patients received pegIFN-2a and were biopsied at 144h. To avoid non-response to IFN-α, we included only patients without ISIS induction in the pre-treatment liver biopsy. The activation of JAK-STAT signaling was assessed by immunohistochemistry and Western blot using phospho-JAK1 specific antibodies. Gene expression analysis was performed using Affymetrix® Human Genome U 133 Plus 2.0 arrays and Bioconductor packages of R statistical environment.

Results: JAK-STAT signaling was strongly activated only at the 4h time point. Gene expression analysis revealed a > 2 fold induction of 474 ISGs. Based on their expression values across time, 4 distinct gene clusters were identified: very early, early, intermediate and late ISGs. The ISGs in the very early and early cluster were transiently induced at 4h and 16h but didn’t show prolonged upregulation or a second wave of induction. Comparison of pegIFN-2a versus -2b at 144h time point showed no significant difference in the amount of induction or extension of upregulated ISGs, despite the longer plasma half-life of pegIFN-2a.

Conclusions: Despite persistent high serum concentrations, pegIFN-α induces only transient activation of Jak-STAT signaling and transient up-regulation of ISGs in the liver. The superior efficacy of pegIFN-α compared to conventional IFN-α cannot be explained by persistent signaling and ISIS induction during the one-week dosing interval.
Establishment of HEV RNA Reverse Transcriptase PCR Assays for the Diagnosis of Acute and Chronic Hepatitis E
Christopher Dörig1, Anca T. Antonino1,2, Beat Müllerhart1, Amaliolo Telfenti3, Darius Moradpour3, and Roland Sahli3
1Division of Gastroenterology and Hepatology, 2Transplantation Center, and 3Institute of Microbiology, CHUV, University of Lausanne, CH-1011 Lausanne, and 4Division of Gastroenterology and Hepatology, University Hospital Zürich, CH-8091 Zürich

Background: Hepatitis E virus (HEV) infection has emerged as a cause of travel-related and autochthonous acute hepatitis E as well as chronic hepatitis in immunosuppressed patients. While travel-related cases are caused primarily by infections with HEV of genotype 1 (HEV-1), autochthonous cases and chronic cases are due to genotype 3 (HEV-3), which is present between humans and diverse animal species. The aim of this study was to establish HEV RNA detection assays for quantitative viral load testing and genotyping.

Methods: Viral RNA was purified from plasma or serum and converted to cDNA prior to (1) multiplex real-time PCR for HEV RNA quantification and (2) multiplex PCR coupled to DNA sequencing for HEV genotype determination. Real-time PCR was designed to match all known HEV genotypes available in Genbank while PCR was designed using conserved primers flanking a variable region of the HEV RNA.

Results: In a validation panel, the newly developed assays allowed for the reliable detection and genotyping of HEV-1 or HEV-3. Cases of travel-related and autochthonous acute hepatitis E as well as chronic hepatitis E in immunosuppressed patients have been identified using these assays and will be presented in detail. Anti-HEV antibodies were negative in three well-characterized patients with chronic hepatitis E after organ transplantation.

Conclusions: We developed and validated a quantitative HEV RNA detection assay that can now be offered on a routine basis (www.chuv.ch/imu/imu-collaborations-viral-hepatitis). Genotyping can also be offered on selected cases. HEV RNA detection is key in diagnosing chronic hepatitis E in immunosuppressed patients with unexplained transaminase elevations, as serology can be negative in these patients.

Deletion of TRAIL on NK cells is associated with excessive hepatic ischemia-reperfusion injury in mice
R. Fahrner1, M. Trochsl1, N. Corazza2, T. Brunner2, N. Penin2, Darius Moradpour1 and Jérôme Gouttenoire1
1Division of Gastroenterology and Hepatology, CHUV, University of Lausanne, Switzerland and 2Institut de Biologie et Chimie des Protéines, University of Lyon, France

Background: Ischemia-reperfusion injury (IRI) is a key factor that contributes to early and late dysfunction of liver grafts. We hypothesized that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a death ligand with high expression on NK cells significantly impacts IRI.

Methods: C57/BL6 wild-type and TRAIL knock-out mice (TRAIL-/-) were subjected to hepatic IRI. Adoptive transfer of wild-type and TRAIL-/- NK cells was performed into Rag2/-/common gamma null mice. Liver injury was assessed by hepatic neutrophil infiltration, alanine aminotransferase (ALT), aspartate transaminase (AST), hepatic neutrophil activation by myeloperoxidase (MPO) activity. NK cell subsets of the ischemic liver lobes were analysed by flow cytometry. NK cell cytotoxicity was performed in vitro studies.

Results: TRAIL-/- mice exhibit significantly more hepatic damage assessed by ALT and AST levels compared to wild-type mice. Adoptive transfer of TRAIL-/- NK cells to Rag2/-/common gamma-null mice was associated with significantly increased IRI compared to wild-type NK cells. Hepatic neutrophil activation was significantly increased in TRAIL-/- compared to wild-type mice. Staining for CD107a was significantly elevated in ischemic liver lobes of TRAIL-/- compared to wild-type mice. In vitro NK cell cytotoxicity to a Yac-1 cancer cell line was significantly increased in sorted TRAIL-/- NK cells compared to wild-type NK cells.

Conclusions: The results show that the lack of TRAIL on NK cells is associated with an excessive liver injury in a murine model of hepatic IRI via the modulation of NK cell mediated cytotoxicity.

Impact of Glasgow-Blatchford Bleeding Score on Hospital Stay Duration of Patients with Upper GI Bleeding
Marc Girardin, Saskia Ditiseheim, Alain Vonlaufen, Thai Nguyen-Tang, Nicolas Goossens, Isabelle Morard, Emiliano Giostra, Antoine Hadengue, Laurent Spaehr, Jean-Louis Frossard, Jean-Marc Dumonceau
Gastroenterology and Hepatology Service, Geneva University Hospital, Geneva, Switzerland.

Background: Upper gastrointestinal (UGI) bleeding is a frequent cause of hospitalization. Its severity may be assessed before endoscopy using the Glasgow-Blatchford bleeding score (GBS). It has been validated to identify patients who will need clinical intervention. The aim was to prospectively validate the GBS in patients admitted for UGI bleeding in the Geneva County and to use it for shortening the hospital stay in patients predicted at low risk of needing clinical intervention.

Methods: Consecutive consenting patients with UGI bleeding were included between October 2009 and January 2012. A GBS of 0 was used to identify patients who would not need clinical intervention.

In the first part of the study, UGI endoscopy was performed in all patients. In the second part of the study, patients with a GBS=0 were sent home with an appointment for an ambulatory UGI endoscopy. All patients had follow-up at 7 and 30 days. Need for clinical intervention was defined as performance of endoscopic haemostasis, blood transfusion or surgery. Results: 208 patients were included. (14 patients were lost to follow up including 5 deaths). GBS varied from 0 to 18, with 15 (14%) and 11 (11%) patients having a GBS=0 (first and second part of the study). Normal endoscopy was seen in 26% (GBS=0) vs 11% (GBS>0); p<0.05. Clinical intervention was needed in 1/26 (4%) vs. 120/182 (66%) patients with a GBS=0 vs. >0, p<0.0001. In the second vs. the first part of the study, hospital stay was shorter for patients with a GBS=0 (19 vs. 6 hours, P=0.01) while hospital stay did not significantly change for patients with a GBS>0 (7.8 vs. 8.6 days, part 1 vs part 2, respectively). No adverse event was observed in the patients sent home with a GBS=0 during the second part of the study.

Conclusions: Among patients admitted with UGI bleeding, the GBS correctly predicted those who would need intervention. Using the GBS allowed reducing duration and costs of management in patients predicted at low risk of needing a clinical intervention.

Molecular Determinants for Membrane Association of the Hepatitis C Virus NS2 Protease Domain
Christian M. Lange1, Pantxika Blecavec1, Audrey Kennel1, François Penin2, Darius Moradpour3 and Jérôme Gouttenoire3
1Division of Gastroenterology and Hepatology, CHUV, University of Lausanne, Switzerland and 2Institut de Biologie et Chimie des Protéines, University of Lyon, France

Background: Hepatitis C virus (HCV) nonstructural protein 2 (NS2) plays essential roles in particle assembly and polyprotein processing. It harbors an N-terminal membrane domain comprising three putative transmembrane segments that contain charged amino acids (aa) I-93 and a C-terminal cysteine protease domain (aa 94-217). Given that the latter has been predicted to be membrane-associated, we aimed to identify molecular determinants for membrane association of the NS2 protease domain.

Methods: A comprehensive panel of NS2 deletion constructs was analyzed by fluorescence microscopy, selective membrane extraction, and membrane flotation assays. Candidate aa residues involved in membrane association were substituted by site-directed mutagenesis.

Results: The NS2 protease domain alone was found to associate with membranes. Two N-terminal α-helices comprising aa 102-114 and aa 123-136 were found to mediate this association, with conserved hydrophobic and positively charged aa residues representing the key determinants. Interestingly, mutagenesis analyses revealed that electrostatic interactions involving a positively charged aa residue in α-helix 1aaa 123-136 are required for membrane association. Mutations of either monospecific or bispecific (i.e. NS2 cleavage-independent) HCV constructs were prepared to investigate the effect of these substitutions on RNA replication and infectious viral particle formation.

Conclusions: The NS2 protease domain itself harbors molecular determinants for membrane association within α-helices aa 102-114 and aa 123-136 which may contribute to proper positioning of the active site. These results provide new insights into the membrane topology and the poorly understood function of this essential viral protease.
Infection by the hepatitis C virus (HCV) induces several complex physiological changes leading, among others, to insulin resistance (IR). The mechanisms by which HCV alters glucose metabolism are still elusive: it has been shown that IR takes place in both liver and extra-hepatic organs, which are not infected by HCV. Our working hypothesis is that HCV-infected hepatocytes may induce uninfected cells to become insulin resistant via secretion of soluble effectors.

Methods: We co-cultured HCV-infected hepatoma cells with naïve hepatoma cells as well as human skeletal muscle cells and adipocytes. Insulin signalling and metabolic responses of the uninfected cells were analyzed using several approaches.

Results: In uninfected cells, we found a common defect in the insulin signalling pathway: while insulin is still able to promote the phosphorylation of PKB and the majority of its targets, we observed a specific failing in the regulation of AS160 by the hormone. As AS160 is the main PKB’s target involved in regulated lipolysis or lipogenesis.

Conclusions: Our data suggest that HCV-infected cells are able to induce directly IR in uninfected cells, in particular in muscle and adipose cells. Importantly, IR seems to be restricted to glucose metabolism since we did not find any alterations of insulin-regulated lipolysis or lipogenesis.

Proliferative activity in CK7 positive cells and hepatocytes as well as macrophage expansion predict MELD score improvement in decompensated alcoholic liver disease (ALD)

Background: Liver regeneration plays a key role in the prognosis of acute-on-chronic ALD. Both hepatic progenitor cell (HPC) and liver macrophages increase in response to acute liver injury, but the prognostic significance of these changes remains to be determined. We studied the expansion of both macrophage and proliferative HPC compartments on liver biopsies obtained from the bone marrow stem cell trial in ALD, and correlated with the outcome at 3 months.

Methods: 58 patients with decompensated ALD (MELD 19) were included. Proliferative HPC were analyzed (immunohistochemistry) on liver biopsy performed at admission, by manual count of Ki67+ and CK7+ cells. Macrophage expansion was determined by CD68+ morphometric analysis. Cytokines and markers of regeneration were measured by immunoassays on serum and quantitative PCR on liver tissue.

Results

<table>
<thead>
<tr>
<th>Results</th>
<th>Responders</th>
<th>Non responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK7+/Ki67+ cells (HPC)</td>
<td>1.9±1.5</td>
<td>0.9±0.9</td>
</tr>
<tr>
<td>CK7-/Ki67+ cells (mature hepatocytes)</td>
<td>4.1±3.6</td>
<td>1.8±1.4</td>
</tr>
<tr>
<td>Liver macrophages (% of surface area)</td>
<td>4.4%</td>
<td>3.3%</td>
</tr>
</tbody>
</table>

Both hepatocyte growth factor and soluble TNF receptor serum levels were higher in responders. Liver PCR analysis showed that liver macrophagic expansion was associated with an increase in TWEAK receptor mRNA expression (p<0.05), known to stimulate HPC proliferation. Conclusion: This is the first study showing that markers of liver cell proliferation obtained on baseline liver biopsy predicts the clinical outcome at 3 months in patients with decompensated ALD. These data support the role of liver biopsy not only for diagnostic purposes but also to determine the short term prognosis.
Toll-Interacting Protein Modulates Gut Flora Composition, Epithelial Barrier Integrity and Susceptibility to Colitis

Michel H. Maillard 1, Teddy Grandjean 2, Holm H. Uhlig 3, Nicolas Barnich 4, Stéphanie Longet 5, Blaise Corthesy 6, Pierre Michetti 1, Mathias Chamallier 7 and Dominique Vein 1

1 Service of Gastroenterology and Hepatology, CHUV, Lausanne. 2 Institut Pasteur de Lille. 3 Center for Infection and Immunity of Lille, Lille, France. 4 Transplantation and Gastroenterology Unit, University of Oxford. 5 John Radcliffe Hospital, Oxford. 6 Université Clermont 1, Clermont-Ferrand, France. 7 Immunology and allergology, CHUV, Lausanne.

Oral Presentations

Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study

Isabelle Morard 1, Yvan Gasche 1, Mark Kettrman 1, Christian Toso 2, Arnaie Menth 1, Glenda Meegbe 1, Gilles Menth 1, Norman Kretzmer 1, Emilianio Giusto 1

1 Department of Radiology, Geneva University Hospital, Switzerland. 2 Department of Surgery, University of Alberta, Edmonton, Canada. 3 Institute of Transplantation, Geneva University Hospital, Switzerland.

Background: central pontine and extrapontine myelinolysis (CPEPM) is a rare but potentially fatal complication after orthotopic liver transplantation (OLT). The aim of this study was to identify risk factors for CPEPM after OLT and to assess patient outcome.

Methods: we reviewed the clinical data of 1378 patients who underwent OLT between 1987 and 2008 in Geneva, Switzerland and Edmonton, Canada. CPEPM diagnosis, based on neurological symptoms correlated with brain MRI, was made in 19 patients (1.4%). Each of them was compared with 2 control patients without clinical CPEPM matched by age, gender, date of OLT, and MELD score.

Results: 19 patients developed CPEPM (7F, mean age 52.1 ± 2 years, mean MELD score 26 ± 2.2). Indications for OLT were mainly alcoholic (47%) and HCV (21%) cirrhosis. Before OLT, INR values tended to be higher (p=0.059) in patients with CPEPM than in controls. The number of platelet units and fresh frozen plasma (FFP) transfused during surgery was significantly higher in cases of CPEPM (p=0.05 and p=0.047). Hemorrhagic complications after OLT were significantly more frequent in patients who developed CPEPM (p=0.049). After OLT, the values of Na were significantly higher in CPEPM (147.8 ± 2 vs 143.2 ± 0.8, p=0.002), with higher variations of Na before and after OLT (15.9 mmol/l ± 1.9 vs 11.1mmol/l ± 0.9, p=0.023). The first manifestations of CPEPM were observed 9.5 ± 6.5 days after OLT (range 1-25 days). Mortality at one year of patients developing CPEPM was significantly higher (63% vs 13%, p<0.0001).

Conclusion: our study shows that high MELD score patients undergoing OLT, receiving massive perfusions of Na-rich products, experiencing surgery related hemorrhagic complication and important fluctuations of serum Na, are at risk of developing CPEPM, a rare but often fatal neurological complication.

Epithelial Barrier Integrity and Susceptibility to Colitis

Toll-like receptor (TLR) signals are key to maintaining host-microbial interactions. The Toll-interacting protein (Tollip) is an ubiquitously-expressed inhibitor of inflammasome and TLR signaling. We hypothesized that Tollip might control gut homeostasis. Genetic ablation of Tollip did not lead to spontaneous colitis but had dramatic consequences on the intestinal expression of the c-defensin cryptidin 4 and the C-type lectin REGIIIγ. These changes were associated with intestinal dysbiosis and enhanced colonization by segmented filamentous bacteria - a key pro-inflammatory component of the microbiota. Tollip deficiency increased susceptibility to dextran sulfate sodium (DSS) colitis and aggravated chronic TNf-driven colitis in IL-10−/− mice. Flora depletion with antibiotics in Tollip−/− mice was not sufficient to restore DSS colitis susceptibility and deletion of Tollip in non-hematopoietic cells using bone-marrow chimeras was sufficient to increase susceptibility to DSS colitis. After DSS administration, we observed several epithelial defects in Tollip−/− mice including early tight junctions disruption, increased epithelial apoptosis, and increased intestinal permeability. Overall, our data show that Tollip significantly impacts intestinal homeostasis by controlling bacterial ecology and intestinal response to chemical and immunological stresses.

Germ-free mice developed an attenuated portal hypertension in acute and chronic DSS colitis yielding >5000 proteins of which 18 candidates were selected for further investigation in different experimental systems as well as in liver biopsies from patients with chronic hepatitis C.

Results: SILAC coupled protein separation and mass spectrometry, Candidates fulfilling stringent criteria for potential substrates or products of the NS3-4A protease were further investigated in different experimental systems as well as in liver biopsies from patients with chronic hepatitis C.

Conclusion: GPx8 is a proviral factor involved in viral particle production but also a key player in the persistence and pathogenesis of HCV. It cleaves and thereby inactivates two crucial adaptor proteins in viral RNA sensing and innate immunity (MIR17 and TRIF) as well as a phosphatase involved in growth factor signaling (TRC). The aim of this study was to identify novel cellular substrates of the NS3-4A protease and to investigate their role in the replication and pathogenesis of HCV.

Methods: Cell lines inducibly expressing the NS3-4A protease were analyzed in basal as well as interferon-α-stimulated states by stable isotopic labeling using amino acids in cell culture (SILAC) coupled with protein separation and mass spectrometry. Candidates fulfilling stringent criteria for potential substrates or products of the NS3-4A protease were further investigated in different experimental systems as well as in liver biopsies from patients with chronic hepatitis C.

Conclusion: GPx8 is a proviral host factor involved in the viral replication complex and a prime target for antiviral intervention but also a key player in the persistence and pathogenesis of HCV. It cleaves and thereby inactivates two crucial adaptor proteins in viral RNA sensing and innate immunity (MIR17 and TRIF) as well as a phosphatase involved in growth factor signaling (TRC). The aim of this study was to identify novel cellular substrates of the NS3-4A protease and to investigate their role in the replication and pathogenesis of HCV.

Methods: Cell lines inducibly expressing the NS3-4A protease were analyzed in basal as well as interferon-α-stimulated states by stable isotopic labeling using amino acids in cell culture (SILAC) coupled with protein separation and mass spectrometry. Candidates fulfilling stringent criteria for potential substrates or products of the NS3-4A protease were further investigated in different experimental systems as well as in liver biopsies from patients with chronic hepatitis C.

Conclusion: GPx8 is a proviral factor involved in viral particle production but not in HCV entry or HCV RNA replication.

Conclusion: our study shows that high MELD score patients undergoing OLT, receiving massive perfusions of Na-rich products, experiencing surgery related hemorrhagic complication and important fluctuations of serum Na, are at risk of developing CPEPM, a rare but often fatal neurological complication.
Inhibition of SIRT1 impairs growth and autophagy in HCC

Simone Portmann1, Christina Schwarz2, Mario Tscharr1, Daniela Candinas1, Deborah Stroka3

1 Department of Visceral Surgery and Medicine, Inselspital, University Bern, Bern, Switzerland, 2 Department Medical Oncology, Inselspital, University Bern, Bern, Switzerland

Objective: Autophagy is a metabolic process that degrades malfunctioning proteins and removes them to maintain cellular homeostasis. Therefore in HCC, autophagy reduces the efficacy of various anti-tumor therapies. Sirtuins are a highly conserved family of NAD+-dependent deacetylases that target the stability and activity of histone and non-histone proteins. SIRT1 positively regulates autophagy. Our preliminary data has shown that SIRT1 is highly expressed in HCC and inhibition of SIRT1 activity reduces HCC cell autophagy by improving the response to current anti-tumor treatment strategies.

Methods: SIRT1 was inhibited in HCC cell by using small molecule inhibitors. Autophagy was measured by changes in mRNA expression of autophagy-related (ATG) gene and additionally the conversion of LC3I to LC3II was monitored by Western blot. In a next step, HCC lines were treated with Rapamycin to induce autophagy alone and in combination with SIRT1 inhibition.

Results: Inhibition of SIRT1 lead to a decrease in ATG5 mRNA levels compared to DMSO treated controls. In all the HCC cells tested, HCC cells treated with Rapamycin induced LC3I conversion demonstrating that autophagy can be induced in these HCC cell lines. Rapamycin in combination with SIRT1 inhibition impaired LC3II conversion.

Conclusion: SIRT1 is highly expressed in HCC cells and its inhibition decreased basal and Rapamycin-induced markers of autophagy. Preliminary data support further studies for the clinical exploration of SIRT1 inhibitors in combination with Rapamycin for the treatment of HCC.

Better 6 months outcome for steroid refractory ulcerative colitis with infliximab rescue therapy compared to tacrolimus or ciclosporine: a SWISS IBD cohort retrospective analysis

Protic M 1, Schoepfer A2, Frei P 1, Juillerat P 4, Mottet C 3, Mwinyi J 1, Rogler G2, Seibold F 1,4, and the SWISS IBD Cohort study

1 Department of Gastroenterology, Tiefenausspital, Bern 2 Department of Gastroenterology and Hepatology, University Hospital Vaudois, Lausanne 3 Department of Gastroenterology and Hepatology, University Hospital Zürich 4 Department of Gastroenterology, Inselspital University Hospital Bern 5 Gastroenterology Unit, Hôpital Neuchâtelos, Neuchâtelos

BACKGROUND: Ciclosporine (CsA), Tacrolimus (Tcl) and Infliximab (IFX) are effective rescue therapies in steroid-refractory ulcerative colitis (UC). Comparative studies are however missing. METHOD: This is the retrospective analysis of treatment outcome for oral Tc (n=27), initially 0.05mg/Kg twice daily, aiming for serum trough levels of 5-10 ng/ml, intravenous CsA (n=23, 2mg/kg/daily) and then oral CsA 5mg/kg/daily) and IFX (n=43, 5mg/kg intravenously at week 0, 2, 6 and then every 8 weeks in patients with steroid refractory moderate to severe UC enrolled in the SWISS IBD cohort study. After successful rescue therapy with Tc or CsA, thiopurine maintenance therapy or maintenance therapy with TcI (TcI pretreated patients) was introduced. The endpoints analyzed steroid free remission rate (on the basis of modified Truelove-Witts severity index (MTWSI)) and number of colectomies after 6 months. RESULTS: At 6 months, 26% (7/27) of patients treated with TcI remained in steroid free remission (MTWSI score ≤4) compared to 30 % (7/23) on CsA and 58% (17/41) of patients treated with IFX (Tc vs CsA vs IFX p= 0.010). Significant more patients had primary non response, loss of response or severe adverse events in the CsA cohort (61%, 14/23) compared to TcI cohort (33.3 %, 9/27), and IFX cohort (30%, 13/43) (p = 0.037). Colectomy rate was significantly higher after CsA (17.4 %, 4/23) compared to TcI (3.7 %, 1/27) or IFX (2.3 %, 1/43) (p= 0.047).CONCLUSION: After six month, rescue therapy with IFX had the lowest colectomy rate, significantly higher steroid free remission rate, and the lowest rate of non-response, loss of response and severe adverse events compared to CsA or TcI rescue treatment.

Early Results of the Swiss Multicentre Bypass Or Sleeve Study (SM-BOSS): a prospective randomized trial comparing Laparoscopic Sleeve Gastrectomy (LSG) and Laparoscopic Roux-Y-Gastric Bypass (LYRGB)

Ralph Peterli1, Yves Borbély2, Beatrice Kern1, Markus Gass1, Thomas Peters1, Martin Thurnheere1, Bernd Schultes1, Kurt Laederach2, Marco Büeter1, Marc Schiesser1

1 Claraspital, Basel, 2 Inselspital, Bern, 3 Kantonsspital St.Gallen, Universitätsspital Zürich

Objective: LSG has been proposed as an effective operative alternative to the current standard procedure, the LRYGB. Prospective data comparing the two procedures are rare. Therefore, we performed a randomized clinical trial assessing the effectiveness and safety of the two operative techniques. Here we report on early results.

Methods: In all, 217 patients were recruited/randomized at 4 bariatric centres in Switzerland. In 107 patients a LSG was performed using a 35F bougie with suturing of the stapler line. In 110 patients a LRYGB was performed with a 150cm antecolic alimentary and a 50cm biliar pancreatic limb and with a linear or circular stapled anastomosis. The mean BMI of all patients was 36 (35-61) kg/m2, the mean age was 43 (19-65) years, and 73% were female.

Results: The two groups were equal in terms of BMI, age, gender, co-morbidities, and total length of hospitalisation. Mean operative time was lower for LSG than in LRYGB (86 (40-300) min. versus 109 (40-300) min., p<0.002). The conversion rate was 0.9% in LSG versus 1.8% in LRYGB (n.s.). Total complications (Clavien-Dindo score >2) occurred more often in LRYGB (17.2%) than in LSG (8.4%, p<0.05). However, the difference in severe complications (Clavien-Dindo score >2) was not statistically significant (1.9 % for LSG versus 3.6% for LRYGB).

Conclusions: LSG can be performed faster with fewer total complications than can LRYGB but the difference in severe complications was not significant.
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection

Monika Rau1, Felix Stickle2, Stefan Russmann1, Michael Weiskopf2, Johannes Schmitt2,3, Michael T. Diff4, Jean-François Dutour5, Durais Muradopour6, David Sermela1, Beat Müllerhaupt1 and Andreas Geier1

1Department of Gastroenterology and Hepatology, USZ, 2Division of Hepatology, Department of Medicine II, UKK Würzburg, Germany; 3Institute of Clinical Pharmacology, University of Berne; 4Department of Clinical Pharmacology and Toxicology, USZ, Clinical Trials Center, USZ; 5Division of Gastroenterology and Hepatology, USY; 6Division of Gastroenterology and Hepatology, CHUV; 7KSSG

Background: Treatment of chronic hepatitis C is evolving, and direct acting antivirals (DAAs) are now added to pegylated interferon (PEG-IFN)-α and ribavirin (RBV) for the treatment of hepatitis C virus (HCV) genotype 1 infected patients. Different DAAs induce different side effects and can worsen RBV induced hemolytic anemia. Therefore, identifying host genetic determinants of RBV bioavailability and therapeutic efficacy will remain crucial for individualized treatment. Recent data showed associations between RBV induced hemolytic anemia and genetic polymorphisms of concentrated nucleoside transporters such as SNT3 (SLC29A3) and inosine triphosphatase (ITPA). To analyze the association of genetic variants of SLC29A3 transporters and ITPA with RBV induced hemolytic anemia and treatment outcome. Methods: In our study, 173 patients from the Swiss Hepatitis C Cohort Study and 22 patients from Swiss Association for the Study of the Liver study 24 (61% HCV genotype 1, 39% genotypes 2 or 3) were analyzed for SLC29A3 single nucleotide polymorphism (SNP) rs11854484, SLC29A3 n56350726 and SLC29A3 rs1086183 as well as ITPA SNPs rs1277354 and rs7270101. RBV serum levels during treatment were measured in ITPA genotype TT patients. Results: SLC29A3 rs11854484 genotype TT was associated with significantly higher dosage- and body weight-adjusted RBV levels as compared to genotypes TC and CC (p=0.04 and p=0.02 at weeks 4 and 8, respectively). ITPA rs7270101 were associated with hemolytic anemia both in genotype and as allele in allelic analyses. SLC29A3 n56350726 genotype TT (vs. AT/AA; RR=2; 95% CI 1.1-4.4) as well as the T allele of ITPA rs7270101 (vs. TT; RR=1.8, 95% CI 1.1-3.2) were associated with increased SVR rates. The combined analysis of overall ITPA activity and SLC29A3 variants together revealed no significant additive effects on either treatment outcome or SVR. Conclusions: The newly identified association between RBV serum levels and SLC29A3 rs11854484 genotype as well as the replicated association of ITPA and SLC29A3 genetic polymorphisms with RBV induced hemolytic anemia and treatment outcome is a first step in our further studies on host genetic determinants of RBV bioavailability and therapeutic efficacy for individualized treatment of chronic hepatitis C.

Intestinal inflammation induces alterations in enterohepatic Fgf15 signaling as well as changes in biliary and fucal bile acid profile

Monika Rau1,2,3, Bruno Stieger2, Katharina Leucht1, Alexandra Cee1, Josef JG Marin1, Maria J Montel1, Beat Müllerhaupt1,4, Gerhard Rogler1, Andreas Geier1

1Department of Gastroenterology and Hepatology, CHUV, 2Division of Clinical Pharmacology and Toxicology, USZ, 3Laboratory of Experimental Hepatology and Drug Targeting, CIBERehd, University of Salamanca, Spain

Background: DSS-induced colitis is a well accepted and frequently used mouse model for inflammatory bowel disease in particular ulcerative colitis. Hepatic changes caused by intestinal inflammation are still poorly understood. Therefore alterations in bile acids metabolism and bile composition in bile and feces in murine colitis. Methods: Intestinal and hepatic target genes of Fgf15 pathway were quantified by RT-PCR in DSS-treated mice (7d, 2% DSS in drinking water) and control mice. Bile acid transporter expression was analyzed by RT-PCR and by western blotting. Fgf15 levels in serum were measured by ELISA. Biliary and fucal bile acid composition was differentiated by 1H NMR spectroscopy. Results: DSS-treated mice showed induction of Fxr expression in ileo-cecal region (higher correspondent concentration of Fgf15 in serum (180% vs. ctrl; p<0.05). In the liver, inhibition of bile acids synthesis could be observed by down-regulation of Cyp7a1 (40% vs. ctrl; p=0.05) that is regulated by Fxr. In addition, expression of bile acid transporters such as Bsep, Ntcp, Mrp2, Mrp3 and Mrp4 were significantly down-regulated. Bile acid composition in bile was significantly different in treated mice with lower levels of hydrophilic bile acids including α- and β-muricholic acid and taurodeoxycholic acid (20%, 20% and 50% vs. ctrl; p<0.05). In feces a trend towards lower levels of free BA was observed. Conclusions: Our results show for the first time a functionally relevant alteration in gut-liver interaction by activated Fgf15 signaling through Fxr activation in ileo-cecal region of DSS-treated mice. Alterations in biliary and fecal bile acid profile need further investigation and are the focus for the current study. Aims: To study alterations in enterohepatic Fgf15 signaling and associated changes in hepatic bile acid metabolism and bile composition in bile and feces in murine colitis.

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Likert Index, CRP, platelets, hemoglobin, and blood leucocytes

Alain Schoepfer1, Christoph Beglinger2, Alex Straumann2, Ekaterina Salomeeva3, Michael Trummer4, Valerie Pitet5, Stephen R. Vavricka2,6,7, Marina Rizzello2,8,9, Salamanca, Spain

Background: Angiosarcoma (AS) of the liver is a rare and highly aggressive tumor of endothelial origin with dismal prognosis. Studies of the molecular biology of angiosarcomas are limited since animal models are missing. Gaining insights into the molecular pathogenesis of this malignancy is crucial for developing new therapeutic strategies. We have previously shown that knockout of β1h in mice results in vascular remodeling of the hepatic microcirculation and eventually results in spontaneous formation of hepatic angiosarcoma (Gastroenterology 2012). The aim of this study is to 1) establish and characterize a cell line from this murine angiosarcoma, 2) to identify the molecular pathways and potential targets and 3) to evaluate the role of antiangiogenics such as sorafenib in the treatment of angiosarcoma.

Methods: Notch1 KO mice developed hepatic AS weeks after KO with 85% portal vein ligation. Liver sinusoidal endothelial cells (LSEC) were isolated from these individul Notch1 KO mice harboring a macroscopic hepatic AS. Cell culture and passaging in LSEC-specific medium led to isolation of a malignant endothelial cell clones. Isolated AS cells were analyzed for endothelial-specific morphological and functional properties (in vitro capillary formation on Matrigel, expression of CD31 and VEGFR2). In vivo vascular casts and in vitro cellular ultrastructure were studied by scanning electron microscopy (SEM). Gene expression of AS LSEC in comparison to freshly isolated normal LSEC from control and Notch1 KO mice without AS was profiled with the Affymetrix Mouse Gene 1.0 ST array. Expression levels were analyzed and further statistical processing was performed by gene set enrichment analysis (GSEA). AS cells were subjected to capillary tube formation assay in the presence or absence of increasing sorafenib concentrations (0.1, 1 and 5 µM).

Results: AS LSEC retained specific endothelial protoperties as tube formation activity, as well as expression of CD31 and VEGFR2. However, SEM analysis revealed differentiated LSEC, with numerous filapodia, loss of sieve plates, loss of fenestrae, and loss of contact to adjacent endothelial cells. Vascular differentiation were observed in vascular casts from angiosarcoma livers. Transcriptome analysis showed massive changes in gene expression identifying fibroblast growth factor receptor 2α, 2β and 3α, insulin-like growth factor oncogene (MET) and vascular endothelial growth factor A (VEGFA) as potential drivers in malignant transformation of hepatic angiosarcoma. Moreover, GSEA revealed that six of the top 20 upregulated chemical and genetic perturbation gene sets were related to myc targets (FDR<0.05). Capillary tube formation ability of AS cells was significantly inhibited by sorafenib in a dose-dependent manner.

Conclusions: We identified Notch1 as LSEC tumor suppressor gene and key player of hepatic angiosarcoma development in our mouse model. Notch1 KO mice together with the isolated murine angiosarcoma cell lines provide a first and important in vitro and in vivo model to study the molecular background and gain new insight in the molecular biology of angiosarcoma as well as to test novel therapeutic strategies.

Conclusions: We identified Notch1 as LSEC tumor suppressor gene and key player of hepatic angiosarcoma development in our mouse model. Notch1 KO mice together with the isolated murine angiosarcoma cell lines provide a first and important in vitro and in vivo model to study the molecular background and gain new insight in the molecular biology of angiosarcoma as well as to test novel therapeutic strategies.

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Likert Index, CRP, platelets, hemoglobin, and blood leucocytes

Alain Schoepfer1, Christoph Beglinger2, Alex Straumann2, Ekaterina Salomeeva3, Michael Trummer4, Valerie Pitet5, Stephen R. Vavricka2,6,7, Marina Rizzello2,8,9, Salamanca, Spain

Background: Fecal calprotectin (FC) is an established non-invasive marker of disease activity in patients with inflammatory bowel disease (IBD). It has been shown to be a better predictor of clinical activity compared with the stool blood test and endoscopy. Further, it is less prone to false positives in the stool blood test, allowing for noninvasive monitoring of disease activity in UC patients.

Methods: To study FC and endoscopic activity in UC patients undergoing complete colonoscopy we prospectively enrolled and scored clinically and endoscopically. Samples from feces and blood were analyzed in UC patients and controls. Results: We enrolled 228 UC patients and 52 healthy controls. Endoscopic disease activity was correlated best with FC (Spearman’s rank correlation coefficient r = 0.818, followed by the Likert Index (r = 0.682), CRP (r = 0.556), platelets (r = 0.488), blood leucocytes (r = 0.401), and hemoglobin (r = 0.388)). FC was the only marker that could discriminate between different grades of endoscopic activity (grade 0, 16 [10-30] µg/g; grade 1, 35 [25-48] µg/g; grade 2, 102 [44-159] µg/g; grade 3, 225 [176-319] µg/g; grade 4, ≥610 [406-860] µg/g; grade 5, ≥1000 µg/g). FC discriminating the different grades). FC with a cutoff of 57 µg/g had a sensitivity of 91% and a specificity of 90% to detect endoscopically active disease (modified Baron Index ≥ 2). Conclusions: FC better correlated with endoscopic disease activity than clinical activity, CRP, platelets, hemoglobin, and blood leucocytes. The structure correlation with endoscopic disease activity suggests that FC represents a useful biomarker for noninvasive monitoring of disease activity in UC patients.
Protein Phosphatase 2A negatively regulates Interferon-α signalling and modulates Hepatitis C viral replication

Vijay Shanker, Francois HT Duong & Markus H Heim

Hepatology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland

Background: In response to viral infection, cells secrete interferons (IFNs) that bind cell surface receptors and activate the Jak-STAT pathway. Jak-STAT signalling is negatively regulated at different levels of the signalling cascade by several inhibitors like Pias, SOCS, USP18 and TTPases. We have previously reported that protein phosphatase 2A (PP2A) is upregulated in HCV infection, and that IFN signalling is impaired in cells expressing a constitutive active form of PP2A (HA-PP2Ac). In the present work we further studied the role of PP2A in IFN-α signalling and in HCV replication.

Methods: Human hepatoma 7 (Huh7) cells were stably transfected with short hairpin siRNA against PP2Ac. Tyrosine phosphorylation of STAT1 (PY-STAT1) was investigated by Western blot. The expression of ISGs was quantified by RT-qPCR. Binding of STAT1 to m67 oligonucleotide probes was assessed with electrophoretic mobility shift assays. The STAT1-PP2Ac association was analysed by co-immunoprecipitation. PP2Ac was transiently silenced in Huh7.5.1 cells using lentiviral based silencing constructs. The role of PP2A for HCV replication was studied using the fully infectious HCV cell culture system. Cell extracts and cell culture supernatants were harvested at different time points and the extracellular infectivity, HCV RNA, and viral proteins were analysed by titration, RT-qPCR and Western blotting, respectively.

Results: We found decreased tyrosine phosphorylation of STAT1 upon IFN-α stimulation in PP2Ac overexpressing cells. The reduction of STAT1 activation resulted in a decreased binding to STAT1 to m67 probe. Consequently, we observed less induction of the ISGs upon IFN-α stimulation. Knockdown of PP2Ac resulted in enhanced STAT1 phosphorylation, STAT1-DNA association and ISG induction. Inhibition of IFN-α signalling by PP2Ac resulted in an impaired antiviral efficacy against HCV, whereas silencing of PP2Ac enhanced the antiviral activity of IFN-α. Interestingly, we also noticed that over-expression of PP2Ac lead to increased HCV replication and that knockdown of PP2Ac reduced viral replication even in the absence of IFN-α.

Conclusion: Our results provide evidences that PP2A inhibits IFN-α signalling and therefore alters the IFN-α antiviral activity. Furthermore, PP2A influences HCV replication independent of IFN-α signalling.

Renal biomarkers and prediction of acute renal failure in patients with cirrhosis and ascites

Belen Ponte, Laurent Spahr, Eric Gerstel, Pierre Lescuyer, Pierre-Yves Martin, Nephrology, Gastroenterology, Internal Medicine, Bioinformatics and Structural Biology, HUG

Background: Renal failure is frequent in hospitalized patients with cirrhosis, with a strong prognostic value. Serum creatinine overestimates renal function, and renal biomarkers of acute renal failure (ARF) need to be assessed. Methods: This is a prospective, observational cohort study in 100 patients with cirrhosis and ascites admitted to hospital. ARF was diagnosed according to AKIN criteria (Acute Kidney Injury Network) with 3 stages of severity (1-3). Plasma and urine levels of cystatin, NGAL and serum creatinine were measured within 24h of admission. Patients’ follow-up was 30 days.

Results: 77 patients were included to date (66% male, age 58 years), of whom 39 developed ARF (severity grade I, II, III: 51%, 31%, 18%). Table: univariate analysis (SD: standard deviation)

<table>
<thead>
<tr>
<th>Variable</th>
<th>ARF (n=39)</th>
<th>No ARF (n=38)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>49%</td>
<td>21%</td>
<td>0.011</td>
</tr>
<tr>
<td>Creatinine (umol/l) (SD)</td>
<td>135 ± 93</td>
<td>64 ± 24</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Plasma NGAL (ng/ml) (SD)</td>
<td>89 ± 66</td>
<td>71 ± 77</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Urine NGAL/urine creat</td>
<td>7 [0.7-71]</td>
<td>4.4 [0.2-133]</td>
<td>0.02</td>
</tr>
<tr>
<td>Plasma cystatin (mg/l) (SD)</td>
<td>19 ± 0.7</td>
<td>1.2 ± 0.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Age, diabetes or chronic renal insufficiency were not related to ARF. In multivariate analysis, only cystatin (OR 15.2; 95% CI: 3.8-56.7; p<0.001) was associated with ARF, with an AUC of 0.84 (0.70-0.93) for a cut-off of 1.3 mg/l, sensitivity and specificity of 80% and 79%, respectively. Conclusions: This interim analysis suggests that the renal biomarker plasma cystatin is superior to creatinine and NGAL in the early prediction of ARF in patients with cirrhosis and ascites admitted to hospital.

Treatment of Eosinophilic Esophagitis with the CRTH2-Antagonist OC000459: A Novel Therapeutic Principle

Alex Straumann*, Christian Bussmann#, Mike Perkins#, Lisa Pearce Collins#, Roy Petitt#, Michael Hunter#, Jan Steiner# and Hans-Uwe Simon$

*Department of Gastroenterology, University Hospital Basel, Basel, Switzerland
#Oxagen Ltd., Milton Park, Abingdon, Oxon, United Kingdom
$Institute of Pharmacology, University of Bern, Bern, Switzerland

BACKGROUND
Eosinophilic esophagitis (EoE) is a Th2-type inflammatory disease of the esophagus, characterized clinically by symptoms related to esophageal dysfunction and histologically by an eosinophil-predominant inflammation. CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) is a receptor expressed by Th2 cells and eosinophils, which mediates chemotaxis and activation of these cells in response to prostaglandin D2, a key prostanoid in allergic responses. OC000459 is a selective and orally bioavailable CRTH2 antagonist, which blocks the ability of PGD2 to recruit and activate Th2 cells and eosinophils with proven efficacy in asthma. OC000459 is therefore expected to suppress tissue inflammation associated with EoE. The purpose of this study was to evaluate the efficacy and safety of an OC000459 monotherapy in adult patients with active EoE.

METHODS
In this randomized, double-blind, placebo-controlled trial 26 adult patients (m/f = 22:4; mean age 41 years, range 22-69 yrs) with active (≥20 eos/hpf and symptoms), corticosteroid-dependent and/or -resistant EoE were treated either with 100 mg OC000459 (n=14) or placebo (n=12) twice daily for 8 weeks. Pre- and post-treatment disease-activity was assessed clinically, endoscopically, histologically and via biomarkers. The primary endpoint was the reduction of the esophageal eosinophil infiltration.

RESULTS
After an 8-week treatment of active EoE with OC000459, the mean eosinophil number decreased from 114.7 to 74.2 eos/hpf, whereas under placebo, no reduction was observed (from 102.8 to 99.4 eos/hpf) (p=0.196). The effect of OC000459 was more pronounced in the proximal (64% reduction, p=0.131) than in the distal esophagus (16% reduction, p=0.667). The global assessment of disease activity decreased under OC000459 from 7.1 to 5.2 pts, whereas the reduction was less in the placebo group (from 6.7 to 5.8, p=0.424). The endoscopic appearance decreased under OC000459 from 6.3 to 6.5 and increased under placebo from 5.5 to 5.8 pts (p=0.118). In spite of these differences, the symptom score decreased in both OC000459 (from 10.5 to 8.8 pts) and placebo (from 16.7 to 9.8 pts) groups equally (p=0.989). The treatment was well tolerated and no serious adverse events occurred.

CONCLUSIONS
This study demonstrates that 1) treatment with the CRTH2-antagonist OC000459 may exert a moderate anti-inflammatory effect in a subgroup of adult patients with active EoE; 2) the effect is more pronounced in the proximal than in the distal esophagus and; 3) treatment with OC000459 is well tolerated.
Interferon-α induces a sustained expression of interferon stimulated genes that are also upregulated in the liver of patients with chronic hepatitis C and poor response to IFNα-based therapy.

1Trincucci G, Daoung HT, Durand S, Baumann T, and 1Heim MH. University Hospital Basel, Department of Biomedicine, Basel, Switzerland. 1INSERM U748, Institute of Virology, Strasbourg, France.

Background
Hepatitis C virus (HCV) infection is the major cause of cirrhosis and liver cancer. To date, the standard therapy is limited to a combination of Pegylated interferon a (Peg-IFNs) and Ribavirin. However, only 44% and 72% for genotype 1 and 2/3 respectively, show a sustained virological response. We have previously reported that the non-response to IFNα-based therapy is linked to the degree of pre-activation of the IFN system. Indeed, patients with a high expression of interferon-stimulated genes (ISGs) prior treatment will poorly respond to the IFNα-based therapy. The molecular mechanism responsible for the elevated expression of pre-activated ISGs in these non-responder patients remains unclear. One plausible explanation would be that the maintenance of expression of these ISGs results from the activation of the IFNs, signaling since we have reported that IFNα pathway is not refractory to further stimulation by IFNs, contrary to IFNγ. In the present work, we analyze the role of IFNα signaling pathway in the pre-activation of ISGs.

Materials and Methods
IFNα signaling was investigated in human primary hepatocytes (PHH), Huh7, and Huh7 overexpressing the IFNα receptor chain IL28RA (Huh7R). The expression of ISGs was monitored by qPCR. Phosphorylation of STAT1 was experimentally-induced colitis. The clinical impact of hypoxia in patients with inflammatory bowel disease (IBD) is so far poorly investigated.

Aim: We wanted to evaluate if flights and journeys to regions ≥2000 meters above sea level are associated with the occurrence of flares in IBD patients in the following weeks.

Methods: A questionnaire was completed by inpatients and outpatients of the IBD clinics of University hospital Zurich and Lausanne presenting with an IBD flare in the period from Sept 1st 2009 to August 31st 2010. Patients were inquired about their habits in the 4 weeks prior to the flare. Patients with a flare were matched with an IBD group in remission during the observation period (according to age, gender, smoking habits, and medication).

Results: A total of 103 IBD patients was included (43 Crohn’s disease (CD), 54 ulcerative colitis, 60 colonic cancer, mean age 40.1±16.4 years for CD and 43.1±14.2 years for UC). Fifty-two patients with a flare were matched to 51 patients without flare. Patients with a flare had significantly more frequently a flight and/or journey to regions ≥2000 meters above sea level in the observation period compared to the patients in remission (21/52 (40.4%) vs. 8/51 (15.7%), p=0.005). CD patients with a flare had significantly more frequently a flight and/or journey to regions ≥2000 meters above sea level in the observation period compared to the CD patients in remission (8/21 (38.1%) vs. 2/22 (9.1%), p=0.043). A trend for more frequent flights and high-altitude journeys was observed in the UC patients (13/31 (41.9%) vs. 6/29 (20.7%), p=0.077). Mean flight duration was 5.8±4.3 hours. The groups were controlled for the following factors (always flare group cited first): age (37.6±13.4 vs. 45.5±14.6, p=0.005), smoking (16/52 vs. 10/51, p=0.120), regular sports activities (32/52 vs. 33/51, p=0.739), treatment with antibiotics in the 4 weeks before flare (85/22 vs. 75/21, p=0.81), NSAID intake (120/22 vs. 75/21, p=0.221), frequency of chronic obstructive pulmonary disease (both groups 0) and oxygen therapy (both groups 0).

Conclusions: IBD patients with a flare had significantly more frequently a flight and/or high-altitude journey within the four weeks prior to IBD flare compared to the group that was in remission. We conclude that flights and high-altitude stays are a risk factor for IBD flares.

Success rate, continence, and quality of life with a bioprosthetic plug for treating complex anal fistula

Sebastian Wolf1, Ted Ross2, Marc-Olivier Guenin3, Rene Warschkow1, Marcus Burnstein4, Michel Adamin5,6,7,8,9,10

1Kantonsspital St. Gallen, Department of Surgery, St. Gallen, Switzerland; 2Women’s College Hospital, Department of Surgery, University of Toronto, Canada; 3St. Michael’s Hospital, Department of Surgery, University of Toronto, Canada; 4Heidelberg, Division of Medical Biometry, Heidelberg, Germany; 5St Michael’s Hospital, Department of Surgery, University of Toronto, Canada.

Objective: Complex anal fistula continue to challenge surgeons and patients alike. Enthusiastic results from single centres in favor of a bioprosthetic plug (BP) were tempered by further studies. The present work prospectively assessed the success rate, continence, and quality of life following BP surgery in the context of a multicentre study.

Methods: Patients with complex anal fistula of cryptoglandular origin were prospectively included. Four colorectal surgeons participated. Patients were evaluated before surgery, at 10 days, 6 weeks, and 6 months. At each visit, clinical examination was performed and the Fecal Incontinence Score Index (FISSI) and SF36 were completed.

Results: 47 patients (31 male, 16 female) were operated on between October 2006 and March 2009 for high transsphincteric fistula. Twenty (42.6%) fistula were branched or multiple. Seven patients (15%) had the BP as their first fistula surgery, while 40 patients (85%) had 2 - 4 prior fistula surgeries. Six patients (13%) had a redo BP surgery. Median operative time was 25 min. and median length of hospital stay was 1 day. Median follow-up was 7 months (range 4-34 months). Five patients (8.5%) failed their BP within 10 days. Further 4 failed within 6 weeks and 11 more patients failed at 6 months, yielding a 6-month failure rate of 40.4%. Ultimately, a total of 24 patients (51.1%) failed the BP for a median time to recurrence of 9.4 months (95% CI 6.5 - 12.4 months), including 3 patients lost to follow-up. At 6 months of follow-up, the FISSI score improved markedly from 18 to 12 (p=0.008). Six out of 8 quality of life components increased significantly (p<0.004). Accordingly, both quality of life summary scores physical (47.0 vs. 56.2, p=0.001) and mental (47.6 vs 55.3, p=0.013) improved markedly.

Conclusion: The BP allows for a healing rate close to 50% in complex cryptoglandular fistula while improving fecal continence and quality of life. These results support the use of the BP as a first line therapy instead of more aggressive and potentially debilitating surgical options.
Red blood cell transfusions are associated with increased rebleeding in patients with nonvariceal upper gastrointestinal haemorrhage.

Sophie Restellini1, M.D. Omar Kherad2, M.D., Vipul Jairath3, M.D., Myriam Martel B.Sc4, Alan Barkun, M.D., C.M., M.Sc4.

1. Department of Internal Medicine and Rehabilitation and Geriatric; Division of General Internal Medicine, Geneva’s University Hospitals and University of Geneva, Geneva, Switzerland.
2. Department of Internal Medicine, La Tour Hospital and University of Geneva, Geneva, Switzerland.
3. NHS Blood & Transplant and Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
4. Department of Medicine, Division of Gastroenterology, McGill University, Montreal, Canada.

Corresponding author: Sophie Restellini, MD
Department of Internal Medicine and Rehabilitation and Geriatric
Geneva’s University Hospitals and University of Geneva
4 Rue Gabrielle Perret-Gentil
1211 Geneva 14 / Switzerland
Tel: +41 22 372 9540; fax: +41 22 372 9905
E-mail: sophie.restellini@hcuge.ch

BACKGROUND:
Acute upper gastrointestinal hemorrhage (UGIH) is one of the leading clinical indications for transfusion of Red Blood Cells (RBCs). There exists considerable practice variation and little evidence to guide effective use of transfusion of RBCs in the majority of patients who are not in shock. Studies in other critically unwell patients suggest associations between transfusion and adverse patient outcomes. The aim of this study is to determine the association between RBC transfusions administered within 24 hours following presentation to hospital in patients with non-variceal upper gastrointestinal bleeding (NVUGIB) and the clinical outcomes of rebleeding and mortality.

METHODS:
Observational study based on the Canadian Registry of patients with Upper Gastrointestinal Bleeding and Endoscopy (RUGBE). This study included 1869 randomly selected patients admitted to 21 hospitals between 1999 and 2002 with endoscopically confirmed NVUGIB. Transferred patients were then excluded, yielding 1677 patients for this analysis. Multivariate logistic regression models were used to examine the associations between RBC transfusion and patient outcomes.

RESULTS:
One thousand six-hundred and seventy-seven patients were included in the analysis (68.2 +/- 16.8 yrs, 61.7% male, 2.5 +/- 1.7 comorbic conditions, hemoglobin, 96.8 +/- 27.2 g/l). 53.7% of all patients received an RBC transfusion with a mean of 2.9 +/- 1.6 units of blood. 31.6% had haemodynamic instability at presentation. Endoscopy was performed within 24 h in 75.3%; 35.8% exhibited high risk stigmata of hemorrhage, while 35.2% underwent endoscopic therapy. Overall rebleeding (defined as continuous bleeding, rebleeding or surgery) and mortality rates were 17.9% and 5.4%, respectively. After adjusting for potential confounders, transfusion of RBCs within 24 hours of presentation was significantly and independently associated with an increased risk of rebleeding (OR 1.8, 95% CI 1.2-2.8). No significant association was noted between transfusions of RBCs in the first 24 hours and death (OR 1.5, 95% CI 0.94-2.23).

CONCLUSIONS:
The findings of this observational study confirm an association between transfusion of RBCs in patients with NVUGIB and the subsequent risk of rebleeding, after appropriate adjustment for possible confounding. These results support the need for a prospective randomized trial comparing different blood transfusion strategies in patients with UGIH in order to inform safe, effective and judicious use of finite resources.

Fixed Rings and Strictures in Eosinophilic Esophagitis develop Due to Continuing Inflammation over Time
Schoepfer AM1, Sرافonueva E2, Bussmann C1, Netzer P1, Portmann S1, Straumann A2. University Hospital Lausanne/CHUV, 1ISPm, University of Bern, 2Kantonsspital Luzern, 3Gastropraxis Lindenhof, Bern, 4University Hospital Basel

Background and Aims: Two distinct endoscopic phenotypes of Eosinophilic Esophagitis (EoE) have been identified: the inflammatory (IP) and the stenosing (SP) phenotype. It is not known whether these EoE-associated phenotypes are reflective of different phases during disease course. We aimed to assess the phenotype at initial EoE presentation and diagnosis and to evaluate if SP increases over time.

Methods: Retrospective analysis of the Swiss EoE Database (SEED) extended by a review of patients charts, endoscopy and pathology records.

Results: Forty-four EoE patients were analyzed (33 males, mean age at index visit 41 +/- 14 years, all Caucasians). Median follow-up time was 3.1 years (IQR 1-4, range 1-18 years). Median diagnostic delay was 5 years (IQR 2-16, range 0-34 years). At first diagnosis, 32% (14/44) of EoE patients had already presented with a stenosis. The mean diameter of the stenoses was 10 +/- 2 mm and the mean length was 2.8 +/- 2.9 cm. Peak eosinophil count did not change over time (48 +/- 39 eos/HPF at index visit vs. 59 +/- 41 eos/HPF at end of follow-up, p=0.44). The risk of the presence of a stenosis at index visit was 0% for a disease duration of 0-4 years, 37% for a disease duration between 5-10 years and 67% for a disease duration >10 years (p = 0.0035, trend test).

Conclusions: The frequency of esophageal stenoses is proportional to the disease duration, whereas the inflammatory activity does not significantly change over time. Our findings underscore the necessity to reduce diagnostic delay in EoE and to control the underlying inflammatory processes to prevent esophageal remodeling.

Development of the First Disease Activity Index for Eosinophilic Esophagitis: Update on the EEsAI in 2012
Schepopf AM1, Sرافonueva E1, Kuehri C1, Zawhelen M1, Schibli S1, Mueller P1, Bussmann C1, Straussmann A1, EEsAI study group. 1University Hospital Lausanne/CHUV, 2Institute of Social and Preventive Medicine, University of Bern, 3Kantonsspital St. Gallen, 4Kantonsspital Luzern, 5University Hospital Basel

Background and Aims: The international EEsAI study group is currently developing the first activity index (EEsAI) specific for Eosinophilic Esophagitis (EoE). Goal: To develop, evaluate and validate the EEsAI.

Methods: The development comprises three phases: 1. Selection of candidate items (completed); 2. Evaluation of the activity index in a first patient cohort (in progress, patient recruitment completed); and 3. Validation in a second EoE patient cohort. Focus group interviews with patients were used in phase 1 to generate patient reported outcomes (PRO) according to guidelines of regulatory authorities (FDA and EMA), whereas the section of biologic items was developed by Delphi rounds of international EoE experts from Europe and North America.

Results: The EEsAI has a modular composition to assess the following components of EoE activity: patient reported outcomes, endoscopic activity, histologic activity, laboratory activity, and quality of life (QoL). Definitions for all aspects of endoscopic and histologic appearance were established by consensus rounds among EoE experts. Symptom assessment tools were created that take into account different food consistencies as well as food avoidance and specific processing strategies. The EEsAI is currently evaluated in a cohort of adult EoE patients since March 2011 (patient recruitment completed).

Conclusions: The EEsAI standardizes outcome assessment in EoE trials. The collaboration with international EoE experts as well as following of the guidelines from regulatory authorities will lead to its wide applicability.
Small Bowel Bacterial Overgrowth is found in 71% of IBS Patients and associated Symptoms respond well to Rifaximin in a Phase IV Trial

Meinrad P., Schoepfer AM. Private Practice for Gastroenterology Solothurn, 2 University Hospital Lausanne

**Background and Aims:** The prevalence of small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS) ranges from 43% to 78% as determined by the lactulose hydrogen breath (LHBT) test. Although rifaximin, a non-absorbable antibiotic, has been able to decrease IBS symptoms in placebo-controlled randomized trials, these results were not repeated in phase IV studies. We aimed to assess the prevalence of SIBO in an IBS cohort and to evaluate the response to rifaximin.

**Methods:** IBS patients fulfilled Rome III criteria, had an absence of alarm symptoms, normal fecal calprotectin, and normal endoscopic workup. They underwent lactulose hydrogen breath testing (LHBT) for SIBO diagnosis. Patients with SIBO were treated with rifaximin tablets for 14 days. Symptoms were assessed by questionnaires before rifaximin treatment and at week 6.

**Results:** Hundred-fifty IBS patients were enrolled (76% female, mean age 44 ± 16 years), of whom 106 (71%) were diagnosed with SIBO and consequently treated with rifaximin. Rifaximin treatment significantly reduced the following symptoms as assessed by the symptom questionnaire: bloating (5.5 ± 2.6 before vs. 3.6 ± 2.7 after treatment, p < 0.001), flatulence (5 ± 2.7 vs. 4 ± 2.7, p = 0.015), diarrhea (2.9 ± 2.4 vs. 2 ± 2.4, p = 0.005), abdominal pain (4.8 ± 2.7 vs. 3.3 ± 2.5, p < 0.001) and improved overall well-being (3.9 ± 2.4 vs. 2.7 ± 2.3, p < 0.001). The LHBT was repeated 2-4 weeks after rifaximin treatment in 65/93 (70%) patients. Eradication of SIBO was documented in 85% of all patients (55/65).

**Conclusions:** The results of our phase IV trial indicate that a high proportion of IBS patients tested positive for SIBO. IBS symptoms were significantly diminished following a 2-week treatment with rifaximin.

---

**Increased risk in first-degree relatives with colorectal cancer – is communication between physicians, colorectal-patients and first-degree relatives sufficient in (eastern) Switzerland?**

Sawatzki M, Bamert G, Meyerenger C, Sulz MC

**Background:** Colorectal cancer (CRC) contributes significantly to the global burden of cancer [1], and familial clustering of CRC is also common, an estimated-proportion up to 5% of the population have a first-degree relative (FDR) with CRC [2, 3]. Those with one first-degree relative experience a 2-fold higher risk of CRC, but 69% of all (respectively 40.8% of those aged > 50 years) did not undergo a screening colonoscopy. Figure 1 and 2 demonstrate the type of physician informing about raised risk.

**Methods:** We consulted in a retrospective single center cohort all index-patients aged 18-80 who underwent surgery for CRC between January 2004 and May 2010 (64 months) at Kantonsspital St. Gallen. With written approval by the index patients, we contacted their FDR (siblings and children) to fill out a questionnaire. We examined the rate of index patients and FDR who were educated about the higher CRC risk (with specification of the educator) and the rate of already realised screening colonoscopy by FDR. The study was approved by the local ethical committee.

**Results:** The questionnaire return rates were 34.4% (134/390, median age 66.1, male 66.4%), and 69.7% (168/241, median age 43.5, male 50.6%) for index patients and their FDR (49 siblings and 119 children) respectively. 82.1% (110/134) of index patients were informed about the increased CRC risk of their FDR, 85.1% (143/168) of FDR were informed about their increased CRC risk, but 69% of all (respectively 40.8% of those aged > 50 y) did not undergo a screening colonoscopy. Figure 1 and 2 demonstrate the type of physician informing about raised risk.

**Conclusions:** CRC patients and their FDR are well informed about the increased CRC risk of FDR. However, the majority of FDR do not undergo the recommended screening colonoscopy. Therefore further investigation is needed.
**Chronology of Extraintestinal Manifestations relative to IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort**

Vavricka SR,1, Gantenbein C,1, Spoerri M,1, Prinz Vavricka M,2, Navarini A,3, Safroneeva E,1, Fournier N,1, Straumann A,5, Rogler G,6, Schoepf AM,5, Swiss IBD Cohort Study Group.1 University Hospital Zurich, Zurich, 2Division of Internal Medicine, University of Bern, 3ISPM University of Lausanne, 4University Hospital Basel, 5University Hospital Lausanne

**Background and Aims:** To determine the type and frequency of extraintestinal manifestations (EIM) in IBD patients and to evaluate their clinical behavior.

**Methods:** Analysis of data from the Swiss Inflammatory Bowel Disease Cohort (SIBDCS) which collects data since 2005 on a large sample of IBD patients from hospitals and private practices across Switzerland.

**Results:** At total of 1,143 patients were analyzed (572 (50%) female, mean age 42.1±14.4 years), 629 with Crohn's disease (CD), 501 with ulcerative colitis (UC), and 13 with indeterminate colitis (IC). Of those patients suffering from EIM, 41.7% presented two, 12.4% three, 5.3% four, and 3.2% five EIM during lifetime. The initial EIM presented with the following frequencies: peripheral arthritis (PA) 63.4%, ankylosing spondylitis (AS) 8.1%, primary sclerosing cholangitis (PSC) 6%, uveitis 5.7%, oral aphthosis 5.7%, erythema nodosum (EN) 5%, other 3.6%, pyoderma gangrenosum 1.8%, psoriasis 0.7%. In only 7.1% of cases, the EIM manifested before IBD diagnosis was made (median time of 28 months before IBD diagnosis, IQR 7-60 months), in 92.9% EIM manifested after established IBD diagnosis (median 72 months, IQR 9-147 months).

**Conclusions:** EIM are a frequent problem in IBD patients. The vast majority of EIM manifest after IBD diagnosis has been established. Peripheral arthritis, ankylosing spondylitis, and PSC represent the most frequent first manifestations of an EIM.

---

**Frequency and Type of Side Effects of Immunomodulating Medication in the Swiss Inflammatory Bowel Disease Cohort.**

Sébastien Goçalı†, Valérie Pittet†, Nicolas Fournier†, Ekaterina Safroneeva†, Darius Moradpour†, Alain M. Schoepf†; Swiss IBD Cohort Study Group.1 University Hospital Lausanne/CHUV, 2ISPM University of Bern, 3University Hospital Basel

**Background and Aims:** Most studies reporting on adverse effects (AE) of immunomodulatory bowel disease (IBD) therapy focus on single therapy. We aimed to assess the type and frequency of AE in IBD patients treated with single and multiple drug therapy.

**Methods:** Analysis of data from the Swiss Inflammatory Bowel Disease Cohort (SIBDCS). The following drug categories were analyzed: 5-ASA, azathioprine (Aza), 6-mercaptopurine (6-MP), Methotrexate (MTX), Anti-TNF (infliximab, adalimumab, certolizumab pegol), cyclosporine, tacrolimus and steroids.

**Results:** A total of 1,961 patients were analyzed (977 female, mean age 42.1±14.4 years, 1,169 with Crohn’s disease, 790 with ulcerative colitis, and 42 with indeterminate colitis. 318 (16.2%) patients were not treated with any of the above-mentioned drugs, while 650 (33.2%), 569 (29%) and 424 (21.6%) patients had one, two, and three or more drugs, respectively. 535 (32.6%) patients reported at least one side effect. We found a significant correlation between the number of drugs used by a patient and the frequency of side effects with 17.4% side effects for one drug, 29% for 2 drugs, and 60.6% for three or more drugs (p<0.001). The frequency of side effects for the different drug classes were as follows: 5-ASA (n=880) 10.8%, Aza/6-MP (n=636) 51.9% (pancreatitis in 9%, hepatitis in 2.7%), MTX (n=146) 42.5% (hepatitis in 2.7%), anti-TNF (n=255) 23.1%, cyclosporine (n=49) 10.2%, tacrolimus (n=5) 20%, steroids (systemic or topical, n=1,150) 9.6%.

**Conclusion:** IBD treatment is associated with a significant number of side effects. A direct correlation between the number of simultaneously used drugs and the frequency of AE was observed. Physicians should be vigilant for the occurrence of a variety of potential side effects in their IBD patients.

---

**Anti-TNF Therapy in the Swiss Inflammatory Bowel Disease Cohort**

Philippe Hriz1, Nicolas Fournier1, Ekaterina Safroneeva1, Darius Moradpour1, Alain M. Schoepf1; Swiss IBD Cohort Study Group.1 University Hospital Lausanne/CHUV, 2ISPM University of Bern

**Background:** Anti-TNF drugs (Infliximab (IFX), Adalimumab (ADA), Certolizumab pegol (CZP)) are effective in inducing and maintaining response and remission in inflammatory bowel disease (IBD). However, side effects may lead to a switch of the anti-TNF drug. We aimed to evaluate the frequency and reasons for anti-TNF switches.

**Methods:** Analysis of data from the Swiss Inflammatory Bowel Disease Cohort (SIBDCS). Eighty percent of included patients were recruited in hospitals and 20% from private practice.

**Results:** From 2,058 patients (1,172 with Crohn’s disease (CD), 842 with ulcerative colitis (UC) and 44 with indeterminate colitis (IC)), 772 received at least one anti-TNF. Forty-eight % of patients with CD, 23% with UC, and 30% with IC were ever treated with an anti-TNF drug. There was no gender difference with respect to the frequency of anti-TNF treatment. A total of 584 patients (76%) were treated with one, 142 (18%) with two, and 46 (6%) with three anti-TNF (of which 32 were female). A total of 89% patients were treated with IFX, 28% ADA and 13% CZP. Overall response rate (defined as drop in CDAS >100 points) to anti-TNF was 50%, with best response rates for the first used anti-TNF. Reasons to switch the anti-TNF were in 11% a primary non-response, in 38% a loss of response and in 36% anti-TNF side effects or intolerance (reasons for 15% of treatment failures not documented).

**Conclusion:** Anti-TNF drugs were used in half of the CD patients and in one quarter of UC patients. Anti-TNF drug switch due to insufficient response and/or side effects was necessary in one quarter of IBD patients. IFX was mainly used as first-line therapy. Best response rates were observed for the first used anti-TNF. Following analyses will identify risk median treatment duration as well as risk factors for anti-TNF switch.

---

**Experience with Golimumab as fourth anti-TNF-treatment in Patients with Crohn’s Disease – A Case Series**

Pascal Frei1, Gerhard Rogler1, Luc Biedermann1, Pierre Michetti2

1Division of Gastroenterology and Hepatology, University Hospital Zürich, Zürich
2Gastro-entérologie La Source-Beaulieu, Lausanne

**Background:** Anti-TNF therapies play a crucial role in the treatment of Crohn’s disease (CD). There are three anti-TNF antibodies available for the treatment of severe CD (adalimumab, certolizumab pegol, infliximab). Golimumab is a fourth anti-TNF antibody available for the treatment of rheumatoid arthritis, psoriasis arthritis and ankylosing spondylitis. We report our experience with golimumab in three CD patients with treatment refractory intestinal CD activity and spondarthropathy.

**Methods:** Three CD patients who were previously treated with all three currently available anti-TNFs suffered from severe intestinal activity with abdominal pain and diarrhea and spondarthropathy as documented by an experienced rheumatologist. Golimumab was given as third anti-TNF switch.

**Results:** A 25 year old female patient with severely active Crohn’s colitis showed some improvement of arthralgias but no intestinal activity after 3 injections. A 39 year old male patient with severe Crohn’s colitis showed some clinical improvement after 4 injections. Our experience with golimumab (50mg monthly s.c.) therapy in three CD patients showed some clinical improvement.

**Conclusion:** Our experience with “low dose” golimumab (50mg monthly s.c. without induction therapy) in this small case series shows mixed results for the use of golimumab as “rescue therapy” in CD patients with spondarthropathy and intestinal activity. Unfortunately, there are no clinical trials with golimumab for CD. Data from a large trial seem to support the use of golimumab as induction therapy in ulcerative colitis, however, with much larger doses than used in our patients (Sandborn et al., Gastroenterology 2012:142:Supplement(1): p161: Abstract 943d).
Is There a Relationship Between Information Concerns of G12 Patients and Adherence to Therapy? Results from the Swiss IBD Cohort Study, V Pittet (1), G Rogler (2), C Mottet (1), F Froehlich (1.3), B Burand (1), JP Vader (1), (1) CHUV & University of Lausanne, (2) University of Zürich, (3) University of Basel.

Background: In spite of the reformulating nature of inflammatory bowel diseases (IBD), on average, 40% of IBD patients are non-adherent to treatments. On the other hand, they are often seeking information on their disease. The relationship between information seeking and adherence to treatment is poorly documented. The main aim of this study was to examine this association among IBD patients.

Methods: Use of data from the Swiss IBD cohort study, collected through medical reports and patient self-reported questionnaires, and from a survey conducted to assess information sources and concerns. Crude and adjusted odds ratio (OR) for non-adherence to treatment, 95% CI, were calculated. Differences in the proportions of information sources and themes were compared between adherent and non-adherent patients.

Results: The number of eligible patients was 488; 19% (N=92) were non-adherent to their drug treatment and 69% (N=335) were information seekers. Crude OR was 69% higher among information seekers compared to non-seekers (OR=1.69; 95%CI 0.99-2.87) and the OR=2.39 (95%CI 1.24-4.34) after adjustment for confounders (drug regimen, supplementation medicines use) and main risk factors. Family doctors were 15.2% more often consulted (p=0.019) among adherent-to-treatment patients, as were books and TV (+13.1%; p=0.048) while no difference in proportions was observed for sources like internet or gastroenterologists. Concerns linked to tips for disease management were 14.2% more often searched among non-adherent patients (p=0.028). No difference was observed for the other concerns (research and development on IBD, therapies, basic information on the disease, patients' experiences sharing, miscellaneous).

Conclusion: In Switzerland, IBD patients often seek information and considering this, the family doctor plays an important role in the management of symptoms and everyday life with the disease seemed to be the most pressing information concerns of patients. Results suggest that the family doctor plays an important role in the multidisciplinary care approach needed for IBD patients.

Preliminary gland dilatation in liver transplant recipients: preliminary results of a morphometric and clinical study.

Nicolas Goossens1, Saskia Ditiseheim1, Laura Rubbia-Brandt2, Emiliano Giostra1, Romain Breguet1, Laurent Sparh2
1Gastroenterology/Hepatology, 2Clinical Pathology, 3Radiology, HUG Genève.

We studied the prevalence, histologic findings and clinical associations of peribiliary gland (PBG) dilatation, a poorly defined entity, in patients undergoing liver transplantation (LT) for cirrhosis. Methods: We measured the maximal diameter of PBG at the hilum using morphometric histologic analysis in explanted livers, and collected clinical, biochemical and radiological data at time of LT between 10.2006 to 10.2011. Results: 112/184 patients met the inclusion criteria. Preliminary data on 40 patients are presented (69% male; alcoholic cirrhosis: 57%; ascites: 62%; mean MELD score: 16). Patients with major PBG dilatation (35%) had more advanced liver disease and more severe hepatic encephalopathy (HE) as compared to those without this feature.

Table 1: Clinical characteristics of included patients

<table>
<thead>
<tr>
<th>No/mild PBG dilatation</th>
<th>Major PBG dilatation</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>266</td>
<td>148</td>
</tr>
<tr>
<td>Age (years)</td>
<td>43.9 ± 2.1</td>
<td>50.7 ± 1.2</td>
</tr>
<tr>
<td>MELD</td>
<td>13.2 ± 2.2</td>
<td>22.2 ± 2.7</td>
</tr>
<tr>
<td>Child-Pugh</td>
<td>8.8 ± 0.47</td>
<td>10.8 ± 0.69</td>
</tr>
<tr>
<td>Ascites</td>
<td>16 (57%)</td>
<td>10 (71%)</td>
</tr>
<tr>
<td>Grade 2-3 HE</td>
<td>5 (18%)</td>
<td>10 (71%)</td>
</tr>
<tr>
<td>Alk.Phosph (IU/L)</td>
<td>125 ± 11</td>
<td>118 ± 11</td>
</tr>
<tr>
<td>Bilirubin (umol)</td>
<td>83.3 ± 31</td>
<td>226 ± 61</td>
</tr>
</tbody>
</table>

Conclusion: Major PBG dilatation is not a rare finding in cirrhotic patients undergoing LT and it is associated with more advanced liver disease. Further studies should characterize this finding more fully.
Futility rules in Telaprevir combination treatment

S. De Meyer1, D.J. Bartels2, L. Gritz3, T.L. Kieffer4, L. Bengtsson4, D. Luo5, B.S. Adiwijaya5, R.S. Kauffman5, O. Pichchio6, N. Adda7, Tibotec BVBA, Bethesda, MD; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA; 3Tibotec Inc., Titusville, NJ, USA.

Background: Futility rules for treatment with telaprevir (T) in combination with peginterferon/ribavirin (PR) are implemented to minimize potential evolution of T-resistant HCV variants in patients who are unlikely to benefit from therapy. Preliminary futility rules were established based on Phase 2 results and refined following Phase 3 experience. Retrospective data analyses were performed from ADVANCE, ILLUMINATE, and REALIZE (patients were assigned 12-week T/PR with either 12 or 36 additional weeks of PR (treatment-naive, N=903) or 36 weeks of PR (treatment-experienced, N=266). We evaluated on-treatment HCV RNA levels and SVR in relation to the HCV RNA thresholds (>1000 IU/mL for treatment-naive and or >100 IU/mL for treatment-experienced) and timepoints (Weeks 4, 12 for treatment-naive and Weeks 4, 6, 8, and 12 for treatment-experienced) that were applied in the studies to identify patients unlikely to achieve SVR. A viral dynamic model of T/PR, developed based on data from Phase 3 studies, was used to simulate achievement of SVR with different futility rules. Results: At Week 4, 1.7% (14/844) treatment-naive patients, 0.7% (1/138) prior relapsers, 0% (0/46) prior responders had HCV RNA levels >1000 IU/mL; none of these patients achieved an SVR with continued PR treatment (T was discontinued). Modeling data confirmed this at Week 2, with a subsequent increase in HCV RNA levels by Week 4. Among 16/844 treatment-naive patients and 7/254 treatment-experienced patients with HCV RNA levels between 100-1000 IU/mL at Week 4, 22% (5/23) achieved SVR with continued treatment. Modeling data confirmed patients with 100-1000 IU/mL at Week 4 would benefit from continued T and PR treatment but patients with greater than 1000 IU/mL would not. Conclusion: A futility rule of greater than 1000 IU/mL at Week 4 identified and predicted treatment-naive or -experienced patients unlikely to achieve an SVR, and prevented unnecessary exposure to T and PR in patients unlikely to benefit from further treatment. Additionally, 23/25 of these patients had reached HCV RNA nadir by Week 4 and were experiencing viral breakthrough.

Bone marrow mononuclear cells infusion into the liver is associated with liver macrophage expansion in patients with decompensated alcoholic liver disease (ALD).

Nicolas Lanthier, Laura Rubbia-Brandt, Yves Chalandon, Vincent Kindler, Antoine Hadengue, Laurent Spahr. HUG, Genève.

Background: In decompensated ALD, autologous transplantation of bone marrow mononuclear cells doesn’t improve liver function at 3 months as compared to standard of care (Hepatology 2011, Abstract). We aim to analyze changes in hepatic progenitor cell (HPC) and macrophage compartments associated with this strategy. Methods: We examined liver biopsies obtained at baseline and 12 months of follow-up in 58 patients. Both HPC and macrophage compartments were analyzed using immunohistochemistry for CK7 and CD68 and morphometric analysis. Results: Immunohistochemical staining for CK7 correlated with liver failure as assessed by the MELD score (r=0.33, p=0.05) and at 4-week biopsies (r=0.61; p<0.01), in line with recently published data (Sancho-Bru, Hepatology 2012). Autologous transplantation procedure was not associated with changes in CK7 positive cells at 4-week follow-up biopsy. Table: (CD68 expressed in % of surface area)

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Baseline CD68 (%)</th>
<th>4-week CD68 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>3.7</td>
<td>5.4</td>
<td>0.01</td>
</tr>
<tr>
<td>Standard of care</td>
<td>4.2</td>
<td>4.6</td>
<td>NS</td>
</tr>
</tbody>
</table>

Further analyses of gene expression patterns are planned in order to determine whether those changes in the macrophage compartment are associated modifications in inflammatory or regenerative pathways. Conclusion: Total liver cell CK7 positivity correlates with the degree of liver failure in patients with ALD. Autologous mononuclear bone marrow cell infusion doesn’t increase the number of HPC as compared to standard of care alone, but is associated with an expansion of the macrophage compartment. This is of particular interest, knowing the role of the micro-environment in HPC polarization.

Hyperferritinemia in patients with nonalcoholic fatty liver disease: transient elastometry values in 20 patients

Thao-Dahlia Cao, Nicolas Goossens, Saskia Ditlisme, Marc Girardin, Laurent Sparh HUG Genève.

Serum ferritin (SFer) levels are frequently elevated in patients with nonalcoholic fatty liver disease (NAFLD), in relation with inflammation and/or increased iron stores. It has been shown that increased serum ferritin was associated with advanced liver fibrosis in these patients (Kowdley, Hepatology 2012; 55:77-85). We studied transient elastometry (TE) values using Fibroscan in patients with NAFLD referred to our unit for hyperferritinemia, as defined by sFer > 1.5 upper limit of normal in the absence of HFE mutation. Methods: The data from 22 patients examined between 11.2011 to 4.2012 were reviewed, including available liver biopsy findings and MRI scans to quantify iron deposition. Results: Quality criteria of TE measurement were not met in 2 patients, leaving 20 patients for analysis. The XL probe was used in 4 patients. To date, 8 patients had a liver biopsy or a MRI scan for iron quantification performed. Table: patients characteristics (median values and range, mean ± SD)

| Gender (M/F) | 17/3 |
| Age (yrs) | 55 [36-70] |
| Obesity or overweight (%) | 95% |
| HOMA score | 3.2 [1.5-10.9] |
| Total cholesterol (mmol/l) | 5.3 ± 2.2 |
| ALT (U/L) | 58 ± 52 |
| GGT (U/L) | 88 ± 58 |
| SFer (ug/l) | 716 [501-1575] |
| TE value (kPa) | 5.8 [3.1-14] |

All but 3 patients had TE values < 8 kPa. In the 4 patients with moderate/severe hepatic iron deposition (2 at histology, 2 at MRI), TE values were < 8 kPa. Conclusions: In this small group of patients with NAFLD and hyperferritinemia, the majority of TE values are within the normal range. The usefulness of TE to identify advanced fibrosis in this setting is therefore questionable and requires further studies.

Bone marrow mononuclear cells infusion into the liver is associated with liver macrophage expansion in patients with decompensated alcoholic liver disease (ALD).

Nicolas Lanthier, Laura Rubbia-Brandt, Yves Chalandon, Vincent Kindler, Antoine Hadengue, Laurent Spahr. HUG, Genève.

Background: In decompensated ALD, autologous transplantation of bone marrow mononuclear cells doesn’t improve liver function at 3 months as compared to standard of care (Hepatology 2011, Abstract). We aim to analyze changes in hepatic progenitor cell (HPC) and macrophage compartments associated with this strategy. Methods: We examined liver biopsies obtained at baseline and 12 months of follow-up in 58 patients. Both HPC and macrophage compartments were analyzed using immunohistochemistry for CK7 and CD68 and morphometric analysis. Results: Immunohistochemical staining for CK7 correlated with liver failure as assessed by the MELD score (r=0.33, p=0.05) and at 4-week biopsies (r=0.61; p<0.01), in line with recently published data (Sancho-Bru, Hepatology 2012). Autologous transplantation procedure was not associated with changes in CK7 positive cells at 4-week follow-up biopsy. Table: (CD68 expressed in % of surface area)

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Baseline CD68 (%)</th>
<th>4-week CD68 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>3.7</td>
<td>5.4</td>
<td>0.01</td>
</tr>
<tr>
<td>Standard of care</td>
<td>4.2</td>
<td>4.6</td>
<td>NS</td>
</tr>
</tbody>
</table>

Further analyses of gene expression patterns are planned in order to determine whether those changes in the macrophage compartment are associated modifications in inflammatory or regenerative pathways. Conclusion: Total liver cell CK7 positivity correlates with the degree of liver failure in patients with ALD. Autologous mononuclear bone marrow cell infusion doesn’t increase the number of HPC as compared to standard of care alone, but is associated with an expansion of the macrophage compartment. This is of particular interest, knowing the role of the micro-environment in HPC polarization.

Hyperferritinemia in patients with nonalcoholic fatty liver disease: transient elastometry values in 20 patients

Thao-Dahlia Cao, Nicolas Goossens, Saskia Ditlisme, Marc Girardin, Laurent Sparh HUG Genève.

Serum ferritin (SFer) levels are frequently elevated in patients with nonalcoholic fatty liver disease (NAFLD), in relation with inflammation and/or increased iron stores. It has been shown that increased serum ferritin was associated with advanced liver fibrosis in these patients (Kowdley, Hepatology 2012; 55:77-85). We studied transient elastometry (TE) values using Fibroscan in patients with NAFLD referred to our unit for hyperferritinemia, as defined by sFer > 1.5 upper limit of normal in the absence of HFE mutation. Methods: The data from 22 patients examined between 11.2011 to 4.2012 were reviewed, including available liver biopsy findings and MRI scans to quantify iron deposition. Results: Quality criteria of TE measurement were not met in 2 patients, leaving 20 patients for analysis. The XL probe was used in 4 patients. To date, 8 patients had a liver biopsy or a MRI scan for iron quantification performed. Table: patients characteristics (median values and range, mean ± SD)

| Gender (M/F) | 17/3 |
| Age (yrs) | 55 [36-70] |
| Obesity or overweight (%) | 95% |
| HOMA score | 3.2 [1.5-10.9] |
| Total cholesterol (mmol/l) | 5.3 ± 2.2 |
| ALT (U/L) | 58 ± 52 |
| GGT (U/L) | 88 ± 58 |
| SFer (ug/l) | 716 [501-1575] |
| TE value (kPa) | 5.8 [3.1-14] |

All but 3 patients had TE values < 8 kPa. In the 4 patients with moderate/severe hepatic iron deposition (2 at histology, 2 at MRI), TE values were < 8 kPa. Conclusions: In this small group of patients with NAFLD and hyperferritinemia, the majority of TE values are within the normal range. The usefulness of TE to identify advanced fibrosis in this setting is therefore questionable and requires further studies.
A comprehensive review of patterns of viral load decline in patients treated with telaprevir plus peginterferon and ribavirin

S De Meyer,1 G Picchio,1 I Diernek,1 A Ghys,1 L Griz,1 TL Kieffer,1 DJ Bartels,1 F Tomaka,1 L Bengtsson,1 D Luo,4 RS Kaufman,4 N Adda,4 C Sarrazin1

1Tvibotea BVRA, Brussels, Belgium; 2Tvibotea Inc., Tusville, NJ, USA; 1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 1Johanna Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany

Background: Viral load profiles in chronic hepatitis C virus (HCV) genotype 1-infected patients treated with peginterferon/ribavirin (PR) are characterized by heterogeneous HCV RNA kinetics ranging from rapid virologic response (RVR) to null response, which has implications for how early futility rules can be successfully applied. The introduction of direct-acting antivirals, such as Telaprevir (T), has dramatically changed the characteristics of viral load profiles and has enabled the use of earlier futility rules. In order to familiarize physicians with this new paradigm, we provide a comprehensive review of the most frequent profiles observed in patients treated with T and PR. Methods: HCV RNA profiles from 363 HCV genotype 1 treatment-naive patients enrolled in the ADVANCE study, and 266 prior treatment-failure patients (including prior relapsers, partial responders and null responders) enrolled in the REALIZE study, were reviewed. All patients were assigned to receive 12 weeks of T either with 24 (T12PR24) or 48 weeks (T12PR48) of PR. Results: All patients, irrespective of baseline characteristics and/or prior response to PR (relapse, partial response and null response), experienced a rapid decline in HCV RNA (> 2.0 log10) by Day 14, indicating that null response to T/PR is unlikely to occur. Subsequently, HCV RNA continued to decline to undetectable levels in patients with sustained virologic response (SVR), late virologic breakthrough (vBT; after Week 12, i.e. during the PR phase), or relapse. In patients with early vBT or meeting a futility rule before Week 12, HCV RNA usually never became undetectable and/or increased rapidly after reaching the nadir. Conclusions: HCV RNA profiles with T/PR are different from those with PR alone. It is important that clinicians understand these new HCV RNA profiles for proper application of futility rules. The HCV RNA dynamics allow for more stringent and earlier implementation of futility rules for patients who would not benefit from continued treatment.
Hepatoprotective Properties of a Toll-like Receptor 5 Agonist

Adrian Keogh 1, Yitzhak Zimmer 2, René Fahrner 1, Michaela Modova 1, Andrei Gudkov 1, Daniel Aebersold 1, Daniel Candinas 1 and Deborah Stroka 1

1 Clinic of Visceral Surgery and Medicine, 2 Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland

Background and Aims: CBLB502, an agonist of Toll-like receptor 5, has been shown to have radioprotective activity in mouse and primate models. Here we investigate hepatoprotective effect of the compound in radioprotection of human hepatocytes and in an ischemia reperfusion model in rodents.

Methods: Isolated human hepatocytes were exposed to 100 Gy +/- 4ng/ml CBLB502, cell viability and function was measured. A rodent ischemia reperfusion model was also used to investigate the hepatoprotective effect of CBLB502 via ALI/AST and myeloperoxidase levels.

Results: Isolated human hepatocytes possess the TLR-5 receptor and CBLB502 activates nuclear factorkB signaling. Irradiation of human hepatocytes with 100 Gy caused no obvious effect on cell viability over the time course used (1-5 days post irradiation). However the ability to induce CYP3A4 was markedly reduced by the irradiation. Incubation of the hepatocytes with 4ng/ml CBLB502 30 minutes prior to irradiation significantly improved the ability to induce CYP3A4 (p<0.05) and returned it to the level of the unirradiated cells. Preliminary results show that CBLB502 provides beneficial influence on clinical symptoms of hepatic ischemia reperfusion injury in our mouse model by reduced serum transaminases (p<0.05) and reduced myeloperoxidase activity reflecting reduced neutrophil infiltration (p<0.0005).

Conclusion: Activation of TLR-5 has a radioprotective effect in isolated human hepatocytes as shown by CYP3A4 induction, although viability was not affected possibly due to their lack of proliferation in culture. Ischemia-reperfusion (I/R) injury associated with hepatic resections and liver transplantation remains a serious complication in clinical practice, which could potentially be diminished by TLR-5 activation.

Monitoring of c-reactive protein detects septic complications in laparoscopic colorectal surgery long ahead clinical signs

Franziska När 1, Bianka Hummel 1, René Warschikow 1,2, Thomas Rudich 1, Thomas Steffen 1, Michel Adamina 1

1 Kantonsspital St. Gallen, Department of Surgery, St. Gallen, Switzerland
2 Division of Medical Biometry, University of Heidelberg, Germany

Background: This work assessed the diagnostic accuracy of CRP level in the detection of septic complications after laparoscopic colorectal resection.

Methods: Patients were identified from a prospective database. Complications were graded according to the Dindo-Clavien classification. CRP was measured on postoperative days 2, 4, and 6. Multivariate and receiver operating curves analysis were performed.

Results: 355 patients were operated between 1998 and 2011 for diverticulosis (88.7%), neoplasia (6.8%), and inflammatory bowel disease (2%). Left, right, and total laparoscopic colectomies were performed in 316 (89%), 33 (9.3%), and 6 patients (1.7%). While complications occurred in 74 patients (36.6%), 51 patients (14.4%) suffered from a septic complication at a median of 6 days. Overall, CRP peaked on day 2. Yet, patients developing septic complications peaked again and worsened on day 6. A CRP above 56mg/l on postoperative day 4 had a sensitivity of 100% (95% CI 0.8-1.0) and a specificity of 99% (95% CI 0.4-0.6) for the development of septic complications in the absence of clinical signs. This translated into a remarkable diagnostic accuracy of 78% (95% CI 0.7-0.9).

Conclusions: Monitoring CRP level in laparoscopic colorectal resection demonstrated a high diagnostic accuracy for septic complications and preceded clinical signs by 2 days.

Implantation of prophylactic non-absorbable intraperitoneal mesh in patients with peritonitis is safe and feasible

Anita Kurmann, Corina Barnetta, Daniel Candinas, Guido Beldi

Department of Visceral Surgery and Medicine, Inselspital University Hospital Bern and University Bern, Bern, Switzerland.

Background: Patients with peritonitis undergoing emergency laparotomy are at increased risk for postoperative open abdomen and incisional hernia. This study aimed to evaluate the outcome of prophylactic intraperitoneal mesh implantation compared with conventional abdominal wall closure in patients with peritonitis undergoing emergency laparotomy.

Methods: A matched case-control study was performed. To analyze a high risk population for incisional hernia formation, only patients with at least two of the following risk factors were included: male gender, body mass index (BMI) >25kg/m², malignant tumor, or previous abdominal incision. In 63 patients with peritonitis, a prophylactic non-absorbable mesh was implanted intraperitoneally between 2005 and 2010. These patients were compared with 70 patients with the same risk factors and peritonitis undergoing emergency laparotomy in one year (2008) who received conventional abdominal closure without mesh implantation.

Results: Isolated human hepatocytes possess the TLR-5 receptor and CBLB502 activates nuclear factorB signaling. Irradiation of human hepatocytes with 100 Gy caused no obvious effect on cell viability over the time course used (1-5 days post irradiation). However the ability to induce CYP3A4 was markedly reduced by the irradiation. Incubation of the hepatocytes with 4ng/ml CBLB502 30 minutes prior to irradiation significantly improved the ability to induce CYP3A4 (p<0.05) and returned it to the level of the unirradiated cells. Preliminary results show that CBLB502 provides beneficial influence on clinical symptoms of hepatic ischemia reperfusion injury in our mouse model by reduced serum transaminases (p<0.05) and reduced myeloperoxidase activity reflecting reduced neutrophil infiltration (p<0.0005).

Conclusion: Activation of TLR-5 has a radioprotective effect in isolated human hepatocytes as shown by CYP3A4 induction, although viability was not affected possibly due to their lack of proliferation in culture. Ischemia-reperfusion (I/R) injury associated with hepatic resections and liver transplantation remains a serious complication in clinical practice, which could potentially be diminished by TLR-5 activation.

Implementation of Enhanced Recovery After Surgery (ERAS) in colorectal surgery is highly cost-effective

Didier Roulin1, Andrea Donadini1, Sylvain Gander2 Catherine Blanc2, Dieter Hahnloser1, and Nicolas Demartines1

1 Department of Visceral Surgery, University Hospital of Lausanne (CHUV), Switzerland.
2 Department of Anaesthesiology, University Hospital of Lausanne (CHUV), Switzerland.

Background Enhanced Recovery After Surgery (ERAS) pathways are known to reduce postoperative complications and to shorten hospital stay. This study evaluates whether the savings related to complications’ reduction leading to diminished length of stay (LOS) outweigh the implementation’s costs.

Methods The first 50 consecutive patients after implementation of ERAS (ERAS group) within a 6 months period were compared to 50 consecutive patients operated one year before its introduction (control group). Primary LOS, readmission within 30 days, complications, and total costs based on costs per day were compared.

Results Primary LOS was significantly shorter in the ERAS group compared to the control group: median 7 (interquartile range 5-12.25) days vs. 10 (7-18) days (P = 0.003). The total number of complications was reduced from 60 in the control group to 49 in the ERAS group (P = 0.64). Readmission rates were similar (n=2 in each group). The savings related to the reduction of LOS were 191 ‘125 EUR. Investments required for the 50 first ERAS patients were 68’963 EUR. The overall cost saving therefore was 2’440 EUR per patient.

Conclusions The financial investment to introduce and maintain an ERAS program are non-negligible, however, ERAS is highly cost-effective even after a short-time period.
Conclusion: 14.9%, p=0.183) were also comparable. Extra-abdominal infections (7.5% vs. cancer surgery patients undergoing bowel preparation with rectal enema only. Results: Twenty-five studies including 6,548 patients were identified. Methodological quality of the eligible studies was low. The majority of studies reported higher rates of anorectal (14 of 18 studies) and male sexual dysfunction (9/10) after pR(C)T. Meta-analysis revealed that stool incontinence occurred more often in irradiated patients (risk ratio (RR=0.60 [95% CI: 0.49, 0.74], p<0.0001) and manometric results were significantly worse after pR(C)T (mean resting pressures -15.0 [95% CI: -29.3, -0.8], p=0.04), maximum squeeze pressures (-30.4 [95% CI: -39.3, 21.5], p=0.0001)). Meta-analysis of erectile dysfunction revealed no statistical significance (RR=1.41 [95% CI: 0.74, 2.72], p=0.30). Six of eight studies and meta-analysis demonstrated no negative effect of pR(C)T on urinary function (RR=1.05 [95% CI: 0.67, 1.65], p=0.82).

Conclusions: Although quality of studies on long-term functional outcome is limited, current evidence demonstrates that pR(C)T negatively affects anorectal and male sexual function after TME.
Impact of preoperative risk factors on the severity of complications after esophagectomy for cancer

Styliani Mantziari, Nicolas Demartines, Henri Vuilleumier, Markus Schäfer

Background
Perioperative care of esophageal cancer has improved recently, but surgery is still associated with high morbidity rates. Targeting reversible risk factors could be a promising approach to reduce postoperative complications and improve patient outcome. This study aimed to assess the role of several preoperative risk factors on the incidence and severity of postoperative complications.

Methods
A series of 95 patients who underwent esophagectomy for cancer from 2000-2001 were identified from our data base. Albumin, BMI, alcohol consumption, smoking, age, and ASA class were investigated as risk factors. Postoperative complications were graded according to a validated 5-point score system; minor complications included grades I-IIIA, major complications grades IIb-V. Multiple regression analysis and ANOVA tests were used to analyze correlation between these risk factors and postoperative complications.

Results
There were 17 patients without complications (17%), 54 patients with minor (57%) and 25 patients with major complications (26%). Age, ASA classification and BMI were not correlated with the incidence and severity of complications. The positive predictive value (PPV) of a BMI <20 to identify patients with complications was 83% and the sensitivity was only 23%. White mean albumin levels were similar in the groups with and without complications. Preoperative albumin was significantly correlated to the occurrence of severe complications (p=0.04). The PPV of albumin levels <30/1 to identify patients with complications was 89%, the sensitivity and the negative predictive value (NPV) were 39% and 76%, respectively. Active smoking was statistically significantly correlated to the occurrence of severe complications as all patients with severe complications were active smokers (p=0.0004). The PPV of active smoking to identify patients with complications was 87%, the sensitivity was 76%, and the NPV was 30%. Active alcohol consumption was not correlated to the incidence or to the severity of complications.

Conclusions
Patients with low albumin levels and active smoking are at increased risk to develop severe complications, whereas alcohol, BMI, ASA and age were of no particular importance. As a consequence, preoperative treatment of malnutrition and a strict non-smoking regimen are valuable targets to reduce patients’ postoperative morbidity.

Hand-assisted laparoscopic nephrectomy in a donor with situs inversus totalis

B. Blaser, L. Di Mare, JP Venetz, N. Demartines and M. Matter

Objectives
Laparoscopic nephrectomy for renal transplantation has become a standard approach for living donors, because it improves donor outcomes, without compromising graft function. Since 2005, the hand-assisted laparoscopic nephrectomy technique is performed systematically in all patient. This video presents the laparoscopic approach for removing the left kidney in a 48-year-old woman with situs inversus totalis. It is known that situs inversus is a confusing anatomy especially by laparoscopy.

Methods
The patient was positioned in the right lateral decubitus position. A Pfannenstiel incision was performed to accommodate the hand device (Gelport) with direct pneumoperitoneum creation. A 12-mm and 10-mm ports were introduced in the left inferior quadrant and left superior quadrant, respectively. An additional 5-mm port was placed in the epigastric region for liver retraction. The left parietocolic groove was opened and the ascending colon mobilized, allowing the exposure of the inferior vena cava and the “left” renal vein. The left (double) renal vein, a superior polar arterial two clips and transected. The kidney was released from its posterior bounds, the renal vein and artery were stapled. After delivery the kidney was placed in an ice bath, flushed (warm ischemic time) and prepared for transplantation in the standardized manner.

Results
Despite situs inversus totalis, the preoperative investigations showed no contraindications for living donation. Duration for nephrectomy was 68 minutes and total operative time was 131 minutes. Warm ischemic time was 220 seconds and cold ischemic time 80 minutes. We did not observe any surgery-related complications. The donor recovered uneventfully. A hospital stay of 9 days was explained by respiratory difficulties.

Conclusions
In our center, living donation is equally shared between right and left nephrectomies based on our own protocol. Therefore, the anatomical abnormality like the presented situs inversus totalis was not considered as a contraindication to live kidney donation. Provided the surgical team has the necessary experience, organ donation in situs inversus totalis is feasible and safe.

Quality Management and Structures of the Certified „Darmkrebszentrum“ at the Kantonsspital Baden

S. Pohle, A. Keerl, C. Caspar, S. Hartmeier, R. Rosenberg, Th. Kocher and all Cooperation Partners of the Darmkrebszentrum Baden

1 Klinik für Allgemein-, Gefäss- und Viszeralchirurgie, 2 Klinik für Innere Medizin, Onkologie, Kantonsspital Baden, Baden, on behalf of the Gastroenterological Network

Background: „Darmkrebszentrum“ is a network of specialists of different medical and care-giving disciplines from the out- and in-patient domain, where patients with colorectal cancer are treated integrated and in all stages of disease. Treatment is based on the published S3-guidelines of colorectal cancer.

Methods: The Department of Surgery at the Kantonsspital Baden (KSB) initiated in 2007/2011 a project to implement a quality management system (DIN ISO 9001) and to fulfill the expert requirements of the German Society of Cancer (Onkozert, DKG).

Results: The “Darmkrebszentrum” of the KSB was certified on May 25th, 2011 and the one-year re-audit was passed successfully on May 7th, 2012. Processes for colorectal cancer patients from practitioners to outpatient clinic, hospital stay, diagnostic and therapeutic procedures, discussion in the interdisciplinary tumor-board and outpatient care were adjusted with partners of the network. Quality aims are yearly defined and checked. A clinical data registry has been established to monitor outcome quality. Process improvement and patient satisfaction were focused. The whole process of implementation of such a cancer network will be presented.

Conclusions: The “Darmkrebszentrum” at the KSB represents the first certified Swiss Colorectal-Cancer-Center. Structures and processes improved significantly for patients and staff members. We aim to achieve a continuous improvement in the care of patients with colorectal cancer.
Primary Sclerosing Cholangitis in the Swiss IBD Cohort Study: Prevalence, Patient Characteristics, and Disease Course

Montserrat Fraga,1 Nicolas Fournier,1 Ekaterina Safoncova,2 Darius Moradpour,1 Stefan Vavricka,1 Alain M. Schoepfl1; Swiss IBD Cohort Study.1 Division of Gastroenterology and Hepatology as well as2 Institute of Social and Preventive Medicine, CHUV, University of Lausanne,3 Institute of Social and Preventive Medicine, University of Bern, Bern, University Hospital, Zurich, Switzerland

Background and Aims: Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation (EIM) in inflammatory bowel disease (IBD). We aimed to assess the prevalence of PSC in the Swiss IBD Cohort Study (SIBDCS) and to identify associated risk factors.

Methods: Data from the SIBDCS were analyzed. Patients with IBD and PSC were compared to patients with IBD but without PSC.

Results: Among 1,961 patients with IBD (1,119 Crohn’s disease; CD; 800 ulcerative colitis, UC; 42 indeterminate colitis, IC), diagnosed between 1955 and 2010, 29 patients with PSC were identified (24 PSC-UC, 4 PSC-CD, 1 PSC-IC). The cumulative PSC prevalence was 3.0% in UC, 2.4% in IC and 0.4% in CD (p <0.001 for PSC-UC vs. PSC-CD). PSC was significantly more prevalent in males as compared to females (risk ratio 2.59, p = 0.016). Mean age at PSC diagnosis was 30 years in males and 38 years in females. PSC was diagnosed either simultaneously with or after IBD. No specific risk factors in terms of family history, disease location or disease activity could be identified when comparing patients with UC with or without PSC. One patient with UC and PSC developed cholangiocarcinoma and was later transplanted. Three other patients underwent liver transplantation because of recurrent bacterial cholangitis or liver failure.

Conclusions: PSC was more prevalent in patients with UC as compared to CD and showed a male predominance. No specific risk factors for PSC development could be identified in patients with UC. PSC was diagnosed either simultaneously with or after IBD.

Brain mitochondrial respiration is specifically impaired in non-resuscitated murine sepsis

René Fahrner1, Guido Beldi1, Stephan M. Jakob2, Jukka Takala2, Daniel Candinas1, Siamak Djafarzadeh2
1 Division of Visceral Surgery and Medicine, 2 Department of Intensive Care Medicine, Inselspital, University Hospital Bern, CH-3010 Bern

Background: Early brain dysfunction is common in sepsis. We hypothesized the presence of impaired mitochondrial respiration in non-resuscitated sepsis.

Methods: Sixteen adult C57BL6 mice were randomized to 18 hours of cecal ligation and puncture (CLP) and to a control group (n=8 each). At the end of the experiment, blood concentrations of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) were measured, and liver, heart and brain mitochondria were isolated. Mitochondrial state 3 and state 4 for complex I-V, using high-resolution respirometry. Alterations in mitochondrial structure were assessed by electron microscopy.

Results: All septic animals showed obvious deterioration of health condition. Systemic levels of TNF-alpha and IL-6 were significantly increased in the CLP group compared to controls (TNF-alpha p=0.008, IL-6 p=0.0003). CLP induced a reduction in brain mitochondrial complex-I-dependent respiration (state 3 p=0.01 and state 4 p=0.03). However, CLP was not associated with altered liver and heart mitochondrial complex I, II- or IV-dependent respiration. Mitochondrial membrane disruption and altered cristae structures were visualized in brain but not in liver or myoccardial mitochondria of CLP mice.

Conclusions: In this 18 hours non-resuscitated murine CLP model, ultrastructural damage specifically of brain mitochondria was accompanied by decreased cellular respiration. Liver and heart mitochondria were not affected.
The numbers refer to the pages of this supplement.

<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blaser B</td>
<td>18 S</td>
</tr>
<tr>
<td>Breitenstein S</td>
<td>2 S</td>
</tr>
<tr>
<td>Cao D</td>
<td>14 S</td>
</tr>
<tr>
<td>Clément S</td>
<td>2 S</td>
</tr>
<tr>
<td>Clerc D</td>
<td>18 S</td>
</tr>
<tr>
<td>Cruz J</td>
<td>15 S, 19 S</td>
</tr>
<tr>
<td>De Meyer S</td>
<td>11 S, 14 S, 15 S</td>
</tr>
<tr>
<td>Dilger K</td>
<td>2 S</td>
</tr>
<tr>
<td>Dill M</td>
<td>2 S</td>
</tr>
<tr>
<td>Ditlisheim S</td>
<td>3 S, 13 S</td>
</tr>
<tr>
<td>Doerig C</td>
<td>3 S</td>
</tr>
<tr>
<td>Fahrner R</td>
<td>3 S, 19 S</td>
</tr>
<tr>
<td>Fraga M</td>
<td>12 S, 19 S</td>
</tr>
<tr>
<td>Frei P</td>
<td>12 S</td>
</tr>
<tr>
<td>Genstorfer J</td>
<td>12 S, 17 S</td>
</tr>
<tr>
<td>Girardin M</td>
<td>3 S</td>
</tr>
<tr>
<td>Godat S</td>
<td>12 S</td>
</tr>
<tr>
<td>Goossens N</td>
<td>13 S</td>
</tr>
<tr>
<td>Gouffinand J</td>
<td>3 S</td>
</tr>
<tr>
<td>Graubardt N</td>
<td>15 S</td>
</tr>
<tr>
<td>Hiroz P</td>
<td>12 S</td>
</tr>
<tr>
<td>Juillerat P</td>
<td>11 S</td>
</tr>
<tr>
<td>Kaddai V</td>
<td>4 S</td>
</tr>
<tr>
<td>Keogh A</td>
<td>16 S</td>
</tr>
<tr>
<td>Kurmann A</td>
<td>4 S, 16 S, 19 S</td>
</tr>
<tr>
<td>Lange C</td>
<td>3 S, 4 S</td>
</tr>
<tr>
<td>Lanthier N</td>
<td>4 S, 14 S</td>
</tr>
<tr>
<td>Mailard M</td>
<td>5 S</td>
</tr>
<tr>
<td>Mantziani S</td>
<td>17 S, 18 S</td>
</tr>
<tr>
<td>Meyrat P</td>
<td>11 S</td>
</tr>
<tr>
<td>Moghadamrad S</td>
<td>5 S</td>
</tr>
<tr>
<td>Montserrat F</td>
<td>19 S</td>
</tr>
<tr>
<td>Morard I</td>
<td>5 S, 15 S</td>
</tr>
<tr>
<td>Morikawa K</td>
<td>5 S</td>
</tr>
<tr>
<td>Naf F</td>
<td>16 S</td>
</tr>
<tr>
<td>Patsenker E</td>
<td>6 S</td>
</tr>
<tr>
<td>Peterli R</td>
<td>6 S</td>
</tr>
<tr>
<td>Pittet O</td>
<td>17 S</td>
</tr>
<tr>
<td>Pittet V</td>
<td>13 S</td>
</tr>
<tr>
<td>Pohle S</td>
<td>18 S</td>
</tr>
<tr>
<td>Ponte B</td>
<td>8 S</td>
</tr>
<tr>
<td>Portmann S</td>
<td>6 S</td>
</tr>
<tr>
<td>Protic M</td>
<td>6 S</td>
</tr>
<tr>
<td>Rau M</td>
<td>7 S</td>
</tr>
<tr>
<td>Restellini S</td>
<td>10 S</td>
</tr>
<tr>
<td>Roulin D</td>
<td>16 S</td>
</tr>
<tr>
<td>Rosenberg R</td>
<td>17 S</td>
</tr>
<tr>
<td>Rothweiler S</td>
<td>7 S</td>
</tr>
<tr>
<td>Safroneeva E</td>
<td>18 S</td>
</tr>
<tr>
<td>Sawatzki M</td>
<td>11 S</td>
</tr>
<tr>
<td>Schoepfer A</td>
<td>7 S, 9 S, 10 S</td>
</tr>
<tr>
<td>Shanker V</td>
<td>8 S</td>
</tr>
<tr>
<td>Spahr L</td>
<td>8 S</td>
</tr>
<tr>
<td>Straumann A</td>
<td>8 S</td>
</tr>
<tr>
<td>Toso C</td>
<td>8 S</td>
</tr>
<tr>
<td>Trincucci G</td>
<td>9 S</td>
</tr>
<tr>
<td>Vavricka S</td>
<td>9 S, 12 S</td>
</tr>
<tr>
<td>Wolf S</td>
<td>9 S</td>
</tr>
</tbody>
</table>